Pregnane X-receptor promotes stem cell-mediated colon cancer relapse
Identifieur interne : 002832 ( Pmc/Corpus ); précédent : 002831; suivant : 002833Pregnane X-receptor promotes stem cell-mediated colon cancer relapse
Auteurs : Chris Planque ; Fatemeh Rajabi ; Fanny Grillet ; Pascal Finetti ; François Bertucci ; Meritxell Gironella ; Juan José Lozano ; Bertrand Beucher ; Julie Giraud ; Véronique Garambois ; Charles Vincent ; Daniel Brown ; Ludovic Caillo ; Jovana Kantar ; André Pelegrin ; Michel Prudhomme ; Jérémie Ripoche ; Jean François Bourgaux ; Christophe Ginestier ; Antoni Castells ; Frédéric Hollande ; Julie Pannequin ; Jean Marc PascussiSource :
- Oncotarget [ 1949-2553 ] ; 2016.
Abstract
Colorectal cancer lethality usually results from post-treatment relapse in the majority of stage II-IV patients, due to the enhanced resistance of Cancer Stem Cells (CSCs). Here, we show that the nuclear receptor Pregnane X Receptor (PXR, NR1I2), behaves as a key driver of CSC-mediated tumor recurrence. First, PXR is specifically expressed in CSCs, where it drives the expression of genes involved in self-renewal and chemoresistance. Clinically, high levels of PXR correlate with poor recurrence-free survival in a cohort of >200 stage II/III colorectal cancer patients treated with chemotherapy, for whom finding biomarkers of treatment outcome is an urgent clinical need. shRNA silencing of PXR increased the chemo-sensitivity of human colon CSCs, reduced their self-renewal and tumor-initiating potential, and drastically delayed tumor recurrence in mice following chemotherapy. This study uncovers PXR as a key factor for CSC self-renewal and chemoresistance and targeting PXR thus represents a promising strategy to minimize colorectal cancer relapse by selectively sensitizing CSCs to chemotherapy.
Url:
DOI: 10.18632/oncotarget.10646
PubMed: 27448961
PubMed Central: 5302934
Links to Exploration step
PMC:5302934Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pregnane X-receptor promotes stem cell-mediated colon cancer relapse</title><author><name sortKey="Planque, Chris" sort="Planque, Chris" uniqKey="Planque C" first="Chris" last="Planque">Chris Planque</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Rajabi, Fatemeh" sort="Rajabi, Fatemeh" uniqKey="Rajabi F" first="Fatemeh" last="Rajabi">Fatemeh Rajabi</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Grillet, Fanny" sort="Grillet, Fanny" uniqKey="Grillet F" first="Fanny" last="Grillet">Fanny Grillet</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Finetti, Pascal" sort="Finetti, Pascal" uniqKey="Finetti P" first="Pascal" last="Finetti">Pascal Finetti</name><affiliation><nlm:aff id="A4"> Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Bertucci, Francois" sort="Bertucci, Francois" uniqKey="Bertucci F" first="François" last="Bertucci">François Bertucci</name><affiliation><nlm:aff id="A4"> Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Gironella, Meritxell" sort="Gironella, Meritxell" uniqKey="Gironella M" first="Meritxell" last="Gironella">Meritxell Gironella</name><affiliation><nlm:aff id="A5"> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Lozano, Juan Jose" sort="Lozano, Juan Jose" uniqKey="Lozano J" first="Juan José" last="Lozano">Juan José Lozano</name><affiliation><nlm:aff id="A5"> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Beucher, Bertrand" sort="Beucher, Bertrand" uniqKey="Beucher B" first="Bertrand" last="Beucher">Bertrand Beucher</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Giraud, Julie" sort="Giraud, Julie" uniqKey="Giraud J" first="Julie" last="Giraud">Julie Giraud</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Garambois, Veronique" sort="Garambois, Veronique" uniqKey="Garambois V" first="Véronique" last="Garambois">Véronique Garambois</name><affiliation><nlm:aff id="A6"> Institut de Recherche en Cancérologie de Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Vincent, Charles" sort="Vincent, Charles" uniqKey="Vincent C" first="Charles" last="Vincent">Charles Vincent</name><affiliation><nlm:aff id="A6"> Institut de Recherche en Cancérologie de Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Brown, Daniel" sort="Brown, Daniel" uniqKey="Brown D" first="Daniel" last="Brown">Daniel Brown</name><affiliation><nlm:aff id="A7"> Department of Pathology, University of Melbourne, Parkville, Australia</nlm:aff></affiliation></author><author><name sortKey="Caillo, Ludovic" sort="Caillo, Ludovic" uniqKey="Caillo L" first="Ludovic" last="Caillo">Ludovic Caillo</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Kantar, Jovana" sort="Kantar, Jovana" uniqKey="Kantar J" first="Jovana" last="Kantar">Jovana Kantar</name><affiliation><nlm:aff id="A8"> Laboratoire de Biochimie, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Pelegrin, Andre" sort="Pelegrin, Andre" uniqKey="Pelegrin A" first="André" last="Pelegrin">André Pelegrin</name><affiliation><nlm:aff id="A6"> Institut de Recherche en Cancérologie de Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Prudhomme, Michel" sort="Prudhomme, Michel" uniqKey="Prudhomme M" first="Michel" last="Prudhomme">Michel Prudhomme</name><affiliation><nlm:aff id="A9"> Service de Chirurgie Digestive, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Ripoche, Jeremie" sort="Ripoche, Jeremie" uniqKey="Ripoche J" first="Jérémie" last="Ripoche">Jérémie Ripoche</name><affiliation><nlm:aff id="A9"> Service de Chirurgie Digestive, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Bourgaux, Jean Francois" sort="Bourgaux, Jean Francois" uniqKey="Bourgaux J" first="Jean François" last="Bourgaux">Jean François Bourgaux</name><affiliation><nlm:aff id="A10"> Service d'Hépato-Gastroentérologie, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Ginestier, Christophe" sort="Ginestier, Christophe" uniqKey="Ginestier C" first="Christophe" last="Ginestier">Christophe Ginestier</name><affiliation><nlm:aff id="A11"> Centre de Recherche en Cancérologie de Marseille, U1068 Inserm, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Castells, Antoni" sort="Castells, Antoni" uniqKey="Castells A" first="Antoni" last="Castells">Antoni Castells</name><affiliation><nlm:aff id="A5"> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Hollande, Frederic" sort="Hollande, Frederic" uniqKey="Hollande F" first="Frédéric" last="Hollande">Frédéric Hollande</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A7"> Department of Pathology, University of Melbourne, Parkville, Australia</nlm:aff></affiliation></author><author><name sortKey="Pannequin, Julie" sort="Pannequin, Julie" uniqKey="Pannequin J" first="Julie" last="Pannequin">Julie Pannequin</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Pascussi, Jean Marc" sort="Pascussi, Jean Marc" uniqKey="Pascussi J" first="Jean Marc" last="Pascussi">Jean Marc Pascussi</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27448961</idno><idno type="pmc">5302934</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302934</idno><idno type="RBID">PMC:5302934</idno><idno type="doi">10.18632/oncotarget.10646</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">002832</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002832</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Pregnane X-receptor promotes stem cell-mediated colon cancer relapse</title><author><name sortKey="Planque, Chris" sort="Planque, Chris" uniqKey="Planque C" first="Chris" last="Planque">Chris Planque</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Rajabi, Fatemeh" sort="Rajabi, Fatemeh" uniqKey="Rajabi F" first="Fatemeh" last="Rajabi">Fatemeh Rajabi</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Grillet, Fanny" sort="Grillet, Fanny" uniqKey="Grillet F" first="Fanny" last="Grillet">Fanny Grillet</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Finetti, Pascal" sort="Finetti, Pascal" uniqKey="Finetti P" first="Pascal" last="Finetti">Pascal Finetti</name><affiliation><nlm:aff id="A4"> Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Bertucci, Francois" sort="Bertucci, Francois" uniqKey="Bertucci F" first="François" last="Bertucci">François Bertucci</name><affiliation><nlm:aff id="A4"> Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Gironella, Meritxell" sort="Gironella, Meritxell" uniqKey="Gironella M" first="Meritxell" last="Gironella">Meritxell Gironella</name><affiliation><nlm:aff id="A5"> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Lozano, Juan Jose" sort="Lozano, Juan Jose" uniqKey="Lozano J" first="Juan José" last="Lozano">Juan José Lozano</name><affiliation><nlm:aff id="A5"> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Beucher, Bertrand" sort="Beucher, Bertrand" uniqKey="Beucher B" first="Bertrand" last="Beucher">Bertrand Beucher</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Giraud, Julie" sort="Giraud, Julie" uniqKey="Giraud J" first="Julie" last="Giraud">Julie Giraud</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Garambois, Veronique" sort="Garambois, Veronique" uniqKey="Garambois V" first="Véronique" last="Garambois">Véronique Garambois</name><affiliation><nlm:aff id="A6"> Institut de Recherche en Cancérologie de Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Vincent, Charles" sort="Vincent, Charles" uniqKey="Vincent C" first="Charles" last="Vincent">Charles Vincent</name><affiliation><nlm:aff id="A6"> Institut de Recherche en Cancérologie de Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Brown, Daniel" sort="Brown, Daniel" uniqKey="Brown D" first="Daniel" last="Brown">Daniel Brown</name><affiliation><nlm:aff id="A7"> Department of Pathology, University of Melbourne, Parkville, Australia</nlm:aff></affiliation></author><author><name sortKey="Caillo, Ludovic" sort="Caillo, Ludovic" uniqKey="Caillo L" first="Ludovic" last="Caillo">Ludovic Caillo</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Kantar, Jovana" sort="Kantar, Jovana" uniqKey="Kantar J" first="Jovana" last="Kantar">Jovana Kantar</name><affiliation><nlm:aff id="A8"> Laboratoire de Biochimie, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Pelegrin, Andre" sort="Pelegrin, Andre" uniqKey="Pelegrin A" first="André" last="Pelegrin">André Pelegrin</name><affiliation><nlm:aff id="A6"> Institut de Recherche en Cancérologie de Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Prudhomme, Michel" sort="Prudhomme, Michel" uniqKey="Prudhomme M" first="Michel" last="Prudhomme">Michel Prudhomme</name><affiliation><nlm:aff id="A9"> Service de Chirurgie Digestive, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Ripoche, Jeremie" sort="Ripoche, Jeremie" uniqKey="Ripoche J" first="Jérémie" last="Ripoche">Jérémie Ripoche</name><affiliation><nlm:aff id="A9"> Service de Chirurgie Digestive, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Bourgaux, Jean Francois" sort="Bourgaux, Jean Francois" uniqKey="Bourgaux J" first="Jean François" last="Bourgaux">Jean François Bourgaux</name><affiliation><nlm:aff id="A10"> Service d'Hépato-Gastroentérologie, CHU Carémeau, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Ginestier, Christophe" sort="Ginestier, Christophe" uniqKey="Ginestier C" first="Christophe" last="Ginestier">Christophe Ginestier</name><affiliation><nlm:aff id="A11"> Centre de Recherche en Cancérologie de Marseille, U1068 Inserm, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Castells, Antoni" sort="Castells, Antoni" uniqKey="Castells A" first="Antoni" last="Castells">Antoni Castells</name><affiliation><nlm:aff id="A5"> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Hollande, Frederic" sort="Hollande, Frederic" uniqKey="Hollande F" first="Frédéric" last="Hollande">Frédéric Hollande</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A7"> Department of Pathology, University of Melbourne, Parkville, Australia</nlm:aff></affiliation></author><author><name sortKey="Pannequin, Julie" sort="Pannequin, Julie" uniqKey="Pannequin J" first="Julie" last="Pannequin">Julie Pannequin</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author><author><name sortKey="Pascussi, Jean Marc" sort="Pascussi, Jean Marc" uniqKey="Pascussi J" first="Jean Marc" last="Pascussi">Jean Marc Pascussi</name><affiliation><nlm:aff id="A1"> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM U1191, Montpellier, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Université Montpellier, Montpellier, France</nlm:aff></affiliation></author></analytic><series><title level="j">Oncotarget</title><idno type="eISSN">1949-2553</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Colorectal cancer lethality usually results from post-treatment relapse in the majority of stage II-IV patients, due to the enhanced resistance of Cancer Stem Cells (CSCs). Here, we show that the nuclear receptor Pregnane X Receptor (PXR, NR1I2), behaves as a key driver of CSC-mediated tumor recurrence. First, PXR is specifically expressed in CSCs, where it drives the expression of genes involved in self-renewal and chemoresistance. Clinically, high levels of PXR correlate with poor recurrence-free survival in a cohort of >200 stage II/III colorectal cancer patients treated with chemotherapy, for whom finding biomarkers of treatment outcome is an urgent clinical need. shRNA silencing of PXR increased the chemo-sensitivity of human colon CSCs, reduced their self-renewal and tumor-initiating potential, and drastically delayed tumor recurrence in mice following chemotherapy. This study uncovers PXR as a key factor for CSC self-renewal and chemoresistance and targeting PXR thus represents a promising strategy to minimize colorectal cancer relapse by selectively sensitizing CSCs to chemotherapy.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Alwan, A" uniqKey="Alwan A">A Alwan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chau, I" uniqKey="Chau I">I Chau</name></author><author><name sortKey="Cunningham, D" uniqKey="Cunningham D">D Cunningham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prud Homme, Gj" uniqKey="Prud Homme G">GJ Prud'homme</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dalerba, P" uniqKey="Dalerba P">P Dalerba</name></author><author><name sortKey="Dylla, Sj" uniqKey="Dylla S">SJ Dylla</name></author><author><name sortKey="Park, Ik" uniqKey="Park I">IK Park</name></author><author><name sortKey="Liu, R" uniqKey="Liu R">R Liu</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X Wang</name></author><author><name sortKey="Cho, Rw" uniqKey="Cho R">RW Cho</name></author><author><name sortKey="Hoey, T" uniqKey="Hoey T">T Hoey</name></author><author><name sortKey="Gurney, A" uniqKey="Gurney A">A Gurney</name></author><author><name sortKey="Huang, Eh" uniqKey="Huang E">EH Huang</name></author><author><name sortKey="Simeone, Dm" uniqKey="Simeone D">DM Simeone</name></author><author><name sortKey="Shelton, Aa" uniqKey="Shelton A">AA Shelton</name></author><author><name sortKey="Parmiani, G" uniqKey="Parmiani G">G Parmiani</name></author><author><name sortKey="Castelli, C" uniqKey="Castelli C">C Castelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ricci Vitiani, L" uniqKey="Ricci Vitiani L">L Ricci-Vitiani</name></author><author><name sortKey="Lombardi, Dg" uniqKey="Lombardi D">DG Lombardi</name></author><author><name sortKey="Pilozzi, E" uniqKey="Pilozzi E">E Pilozzi</name></author><author><name sortKey="Biffoni, M" uniqKey="Biffoni M">M Biffoni</name></author><author><name sortKey="Todaro, M" uniqKey="Todaro M">M Todaro</name></author><author><name sortKey="Peschle, C" uniqKey="Peschle C">C Peschle</name></author><author><name sortKey="De Maria, R" uniqKey="De Maria R">R De Maria</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kreso, A" uniqKey="Kreso A">A Kreso</name></author><author><name sortKey="O Brien, Ca" uniqKey="O Brien C">CA O'Brien</name></author><author><name sortKey="Van Galen, P" uniqKey="Van Galen P">P van Galen</name></author><author><name sortKey="Gan, Oi" uniqKey="Gan O">OI Gan</name></author><author><name sortKey="Notta, F" uniqKey="Notta F">F Notta</name></author><author><name sortKey="Brown, Am" uniqKey="Brown A">AM Brown</name></author><author><name sortKey="Ng, K" uniqKey="Ng K">K Ng</name></author><author><name sortKey="Ma, J" uniqKey="Ma J">J Ma</name></author><author><name sortKey="Wienholds, E" uniqKey="Wienholds E">E Wienholds</name></author><author><name sortKey="Dunant, C" uniqKey="Dunant C">C Dunant</name></author><author><name sortKey="Pollett, A" uniqKey="Pollett A">A Pollett</name></author><author><name sortKey="Gallinger, S" uniqKey="Gallinger S">S Gallinger</name></author><author><name sortKey="Mcpherson, J" uniqKey="Mcpherson J">J McPherson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Todaro, M" uniqKey="Todaro M">M Todaro</name></author><author><name sortKey="Alea, Mp" uniqKey="Alea M">MP Alea</name></author><author><name sortKey="Di Stefano, Ab" uniqKey="Di Stefano A">AB Di Stefano</name></author><author><name sortKey="Cammareri, P" uniqKey="Cammareri P">P Cammareri</name></author><author><name sortKey="Vermeulen, L" uniqKey="Vermeulen L">L Vermeulen</name></author><author><name sortKey="Iovino, F" uniqKey="Iovino F">F Iovino</name></author><author><name sortKey="Tripodo, C" uniqKey="Tripodo C">C Tripodo</name></author><author><name sortKey="Russo, A" uniqKey="Russo A">A Russo</name></author><author><name sortKey="Gulotta, G" uniqKey="Gulotta G">G Gulotta</name></author><author><name sortKey="Medema, Jp" uniqKey="Medema J">JP Medema</name></author><author><name sortKey="Stassi, G" uniqKey="Stassi G">G Stassi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dylla, Sj" uniqKey="Dylla S">SJ Dylla</name></author><author><name sortKey="Beviglia, L" uniqKey="Beviglia L">L Beviglia</name></author><author><name sortKey="Park, Ik" uniqKey="Park I">IK Park</name></author><author><name sortKey="Chartier, C" uniqKey="Chartier C">C Chartier</name></author><author><name sortKey="Raval, J" uniqKey="Raval J">J Raval</name></author><author><name sortKey="Ngan, L" uniqKey="Ngan L">L Ngan</name></author><author><name sortKey="Pickell, K" uniqKey="Pickell K">K Pickell</name></author><author><name sortKey="Aguilar, J" uniqKey="Aguilar J">J Aguilar</name></author><author><name sortKey="Lazetic, S" uniqKey="Lazetic S">S Lazetic</name></author><author><name sortKey="Smith Berdan, S" uniqKey="Smith Berdan S">S Smith-Berdan</name></author><author><name sortKey="Clarke, Mf" uniqKey="Clarke M">MF Clarke</name></author><author><name sortKey="Hoey, T" uniqKey="Hoey T">T Hoey</name></author><author><name sortKey="Lewicki, J" uniqKey="Lewicki J">J Lewicki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merlos Suarez, A" uniqKey="Merlos Suarez A">A Merlos-Suarez</name></author><author><name sortKey="Barriga, Fm" uniqKey="Barriga F">FM Barriga</name></author><author><name sortKey="Jung, P" uniqKey="Jung P">P Jung</name></author><author><name sortKey="Iglesias, M" uniqKey="Iglesias M">M Iglesias</name></author><author><name sortKey="Cespedes, Mv" uniqKey="Cespedes M">MV Cespedes</name></author><author><name sortKey="Rossell, D" uniqKey="Rossell D">D Rossell</name></author><author><name sortKey="Sevillano, M" uniqKey="Sevillano M">M Sevillano</name></author><author><name sortKey="Hernando Momblona, X" uniqKey="Hernando Momblona X">X Hernando-Momblona</name></author><author><name sortKey="Da Silva Diz, V" uniqKey="Da Silva Diz V">V da Silva-Diz</name></author><author><name sortKey="Munoz, P" uniqKey="Munoz P">P Munoz</name></author><author><name sortKey="Clevers, H" uniqKey="Clevers H">H Clevers</name></author><author><name sortKey="Sancho, E" uniqKey="Sancho E">E Sancho</name></author><author><name sortKey="Mangues, R" uniqKey="Mangues R">R Mangues</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hollande, F" uniqKey="Hollande F">F Hollande</name></author><author><name sortKey="Pannequin, J" uniqKey="Pannequin J">J Pannequin</name></author><author><name sortKey="Joubert, D" uniqKey="Joubert D">D Joubert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haraguchi, N" uniqKey="Haraguchi N">N Haraguchi</name></author><author><name sortKey="Utsunomiya, T" uniqKey="Utsunomiya T">T Utsunomiya</name></author><author><name sortKey="Inoue, H" uniqKey="Inoue H">H Inoue</name></author><author><name sortKey="Tanaka, F" uniqKey="Tanaka F">F Tanaka</name></author><author><name sortKey="Mimori, K" uniqKey="Mimori K">K Mimori</name></author><author><name sortKey="Barnard, Gf" uniqKey="Barnard G">GF Barnard</name></author><author><name sortKey="Mori, M" uniqKey="Mori M">M Mori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huang, Eh" uniqKey="Huang E">EH Huang</name></author><author><name sortKey="Hynes, Mj" uniqKey="Hynes M">MJ Hynes</name></author><author><name sortKey="Zhang, T" uniqKey="Zhang T">T Zhang</name></author><author><name sortKey="Ginestier, C" uniqKey="Ginestier C">C Ginestier</name></author><author><name sortKey="Dontu, G" uniqKey="Dontu G">G Dontu</name></author><author><name sortKey="Appelman, H" uniqKey="Appelman H">H Appelman</name></author><author><name sortKey="Fields, Jz" uniqKey="Fields J">JZ Fields</name></author><author><name sortKey="Wicha, Ms" uniqKey="Wicha M">MS Wicha</name></author><author><name sortKey="Boman, Bm" uniqKey="Boman B">BM Boman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olszewski, U" uniqKey="Olszewski U">U Olszewski</name></author><author><name sortKey="Liedauer, R" uniqKey="Liedauer R">R Liedauer</name></author><author><name sortKey="Ausch, C" uniqKey="Ausch C">C Ausch</name></author><author><name sortKey="Thalhammer, T" uniqKey="Thalhammer T">T Thalhammer</name></author><author><name sortKey="Hamilton, G" uniqKey="Hamilton G">G Hamilton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Achuthan, S" uniqKey="Achuthan S">S Achuthan</name></author><author><name sortKey="Santhoshkumar, Tr" uniqKey="Santhoshkumar T">TR Santhoshkumar</name></author><author><name sortKey="Prabhakar, J" uniqKey="Prabhakar J">J Prabhakar</name></author><author><name sortKey="Nair, Sa" uniqKey="Nair S">SA Nair</name></author><author><name sortKey="Pillai, Mr" uniqKey="Pillai M">MR Pillai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shenoy, A" uniqKey="Shenoy A">A Shenoy</name></author><author><name sortKey="Butterworth, E" uniqKey="Butterworth E">E Butterworth</name></author><author><name sortKey="Huang, Eh" uniqKey="Huang E">EH Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chikazawa, N" uniqKey="Chikazawa N">N Chikazawa</name></author><author><name sortKey="Tanaka, H" uniqKey="Tanaka H">H Tanaka</name></author><author><name sortKey="Tasaka, T" uniqKey="Tasaka T">T Tasaka</name></author><author><name sortKey="Nakamura, M" uniqKey="Nakamura M">M Nakamura</name></author><author><name sortKey="Tanaka, M" uniqKey="Tanaka M">M Tanaka</name></author><author><name sortKey="Onishi, H" uniqKey="Onishi H">H Onishi</name></author><author><name sortKey="Katano, M" uniqKey="Katano M">M Katano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sladek, Ne" uniqKey="Sladek N">NE Sladek</name></author><author><name sortKey="Kollander, R" uniqKey="Kollander R">R Kollander</name></author><author><name sortKey="Sreerama, L" uniqKey="Sreerama L">L Sreerama</name></author><author><name sortKey="Kiang, Dt" uniqKey="Kiang D">DT Kiang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lehmann, Jm" uniqKey="Lehmann J">JM Lehmann</name></author><author><name sortKey="Mckee, Dd" uniqKey="Mckee D">DD McKee</name></author><author><name sortKey="Watson, Ma" uniqKey="Watson M">MA Watson</name></author><author><name sortKey="Willson, Tm" uniqKey="Willson T">TM Willson</name></author><author><name sortKey="Moore, Jt" uniqKey="Moore J">JT Moore</name></author><author><name sortKey="Kliewer, Sa" uniqKey="Kliewer S">SA Kliewer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raynal, C" uniqKey="Raynal C">C Raynal</name></author><author><name sortKey="Pascussi, Jm" uniqKey="Pascussi J">JM Pascussi</name></author><author><name sortKey="Leguelinel, G" uniqKey="Leguelinel G">G Leguelinel</name></author><author><name sortKey="Breuker, C" uniqKey="Breuker C">C Breuker</name></author><author><name sortKey="Kantar, J" uniqKey="Kantar J">J Kantar</name></author><author><name sortKey="Lallemant, B" uniqKey="Lallemant B">B Lallemant</name></author><author><name sortKey="Poujol, S" uniqKey="Poujol S">S Poujol</name></author><author><name sortKey="Bonnans, C" uniqKey="Bonnans C">C Bonnans</name></author><author><name sortKey="Joubert, D" uniqKey="Joubert D">D Joubert</name></author><author><name sortKey="Hollande, F" uniqKey="Hollande F">F Hollande</name></author><author><name sortKey="Lumbroso, S" uniqKey="Lumbroso S">S Lumbroso</name></author><author><name sortKey="Brouillet, Jp" uniqKey="Brouillet J">JP Brouillet</name></author><author><name sortKey="Evrard, A" uniqKey="Evrard A">A Evrard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alnouti, Y" uniqKey="Alnouti Y">Y Alnouti</name></author><author><name sortKey="Klaassen, Cd" uniqKey="Klaassen C">CD Klaassen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lemmen, J" uniqKey="Lemmen J">J Lemmen</name></author><author><name sortKey="Tozakidis, Ie" uniqKey="Tozakidis I">IE Tozakidis</name></author><author><name sortKey="Galla, Hj" uniqKey="Galla H">HJ Galla</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saigusa, S" uniqKey="Saigusa S">S Saigusa</name></author><author><name sortKey="Tanaka, K" uniqKey="Tanaka K">K Tanaka</name></author><author><name sortKey="Toiyama, Y" uniqKey="Toiyama Y">Y Toiyama</name></author><author><name sortKey="Yokoe, T" uniqKey="Yokoe T">T Yokoe</name></author><author><name sortKey="Okugawa, Y" uniqKey="Okugawa Y">Y Okugawa</name></author><author><name sortKey="Ioue, Y" uniqKey="Ioue Y">Y Ioue</name></author><author><name sortKey="Miki, C" uniqKey="Miki C">C Miki</name></author><author><name sortKey="Kusunoki, M" uniqKey="Kusunoki M">M Kusunoki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deng, Y" uniqKey="Deng Y">Y Deng</name></author><author><name sortKey="Su, Q" uniqKey="Su Q">Q Su</name></author><author><name sortKey="Mo, J" uniqKey="Mo J">J Mo</name></author><author><name sortKey="Fu, X" uniqKey="Fu X">X Fu</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Lin, Eh" uniqKey="Lin E">EH Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drocourt, L" uniqKey="Drocourt L">L Drocourt</name></author><author><name sortKey="Ourlin, Jc" uniqKey="Ourlin J">JC Ourlin</name></author><author><name sortKey="Pascussi, Jm" uniqKey="Pascussi J">JM Pascussi</name></author><author><name sortKey="Maurel, P" uniqKey="Maurel P">P Maurel</name></author><author><name sortKey="Vilarem, Mj" uniqKey="Vilarem M">MJ Vilarem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Emmink, Bl" uniqKey="Emmink B">BL Emmink</name></author><author><name sortKey="Verheem, A" uniqKey="Verheem A">A Verheem</name></author><author><name sortKey="Van Houdt, Wj" uniqKey="Van Houdt W">WJ Van Houdt</name></author><author><name sortKey="Steller, Ej" uniqKey="Steller E">EJ Steller</name></author><author><name sortKey="Govaert, Km" uniqKey="Govaert K">KM Govaert</name></author><author><name sortKey="Pham, Tv" uniqKey="Pham T">TV Pham</name></author><author><name sortKey="Piersma, Sr" uniqKey="Piersma S">SR Piersma</name></author><author><name sortKey="Borel Rinkes, Ih" uniqKey="Borel Rinkes I">IH Borel Rinkes</name></author><author><name sortKey="Jimenez, Cr" uniqKey="Jimenez C">CR Jimenez</name></author><author><name sortKey="Kranenburg, O" uniqKey="Kranenburg O">O Kranenburg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duong, Hq" uniqKey="Duong H">HQ Duong</name></author><author><name sortKey="Hwang, Js" uniqKey="Hwang J">JS Hwang</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author><author><name sortKey="Kang, Hj" uniqKey="Kang H">HJ Kang</name></author><author><name sortKey="Seong, Ys" uniqKey="Seong Y">YS Seong</name></author><author><name sortKey="Bae, I" uniqKey="Bae I">I Bae</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schafer, A" uniqKey="Schafer A">A Schafer</name></author><author><name sortKey="Teufel, J" uniqKey="Teufel J">J Teufel</name></author><author><name sortKey="Ringel, F" uniqKey="Ringel F">F Ringel</name></author><author><name sortKey="Bettstetter, M" uniqKey="Bettstetter M">M Bettstetter</name></author><author><name sortKey="Hoepner, I" uniqKey="Hoepner I">I Hoepner</name></author><author><name sortKey="Rasper, M" uniqKey="Rasper M">M Rasper</name></author><author><name sortKey="Gempt, J" uniqKey="Gempt J">J Gempt</name></author><author><name sortKey="Koeritzer, J" uniqKey="Koeritzer J">J Koeritzer</name></author><author><name sortKey="Schmidt Graf, F" uniqKey="Schmidt Graf F">F Schmidt-Graf</name></author><author><name sortKey="Meyer, B" uniqKey="Meyer B">B Meyer</name></author><author><name sortKey="Beier, Cp" uniqKey="Beier C">CP Beier</name></author><author><name sortKey="Schlegel, J" uniqKey="Schlegel J">J Schlegel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, D" uniqKey="Zhao D">D Zhao</name></author><author><name sortKey="Mo, Y" uniqKey="Mo Y">Y Mo</name></author><author><name sortKey="Li, Mt" uniqKey="Li M">MT Li</name></author><author><name sortKey="Zou, Sw" uniqKey="Zou S">SW Zou</name></author><author><name sortKey="Cheng, Zl" uniqKey="Cheng Z">ZL Cheng</name></author><author><name sortKey="Sun, Yp" uniqKey="Sun Y">YP Sun</name></author><author><name sortKey="Xiong, Y" uniqKey="Xiong Y">Y Xiong</name></author><author><name sortKey="Guan, Kl" uniqKey="Guan K">KL Guan</name></author><author><name sortKey="Lei, Qy" uniqKey="Lei Q">QY Lei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hu, Y" uniqKey="Hu Y">Y Hu</name></author><author><name sortKey="Smyth, Gk" uniqKey="Smyth G">GK Smyth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Flier, Lg" uniqKey="Van Der Flier L">LG van der Flier</name></author><author><name sortKey="Haegebarth, A" uniqKey="Haegebarth A">A Haegebarth</name></author><author><name sortKey="Stange, De" uniqKey="Stange D">DE Stange</name></author><author><name sortKey="Van De Wetering, M" uniqKey="Van De Wetering M">M van de Wetering</name></author><author><name sortKey="Clevers, H" uniqKey="Clevers H">H Clevers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Powell, Ae" uniqKey="Powell A">AE Powell</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Poulin, Ej" uniqKey="Poulin E">EJ Poulin</name></author><author><name sortKey="Means, Al" uniqKey="Means A">AL Means</name></author><author><name sortKey="Washington, Mk" uniqKey="Washington M">MK Washington</name></author><author><name sortKey="Higginbotham, Jn" uniqKey="Higginbotham J">JN Higginbotham</name></author><author><name sortKey="Juchheim, A" uniqKey="Juchheim A">A Juchheim</name></author><author><name sortKey="Prasad, N" uniqKey="Prasad N">N Prasad</name></author><author><name sortKey="Levy, Se" uniqKey="Levy S">SE Levy</name></author><author><name sortKey="Guo, Y" uniqKey="Guo Y">Y Guo</name></author><author><name sortKey="Shyr, Y" uniqKey="Shyr Y">Y Shyr</name></author><author><name sortKey="Aronow, Bj" uniqKey="Aronow B">BJ Aronow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maugeri Sacca, M" uniqKey="Maugeri Sacca M">M Maugeri-Sacca</name></author><author><name sortKey="Bartucci, M" uniqKey="Bartucci M">M Bartucci</name></author><author><name sortKey="De Maria, R" uniqKey="De Maria R">R De Maria</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oh, Sc" uniqKey="Oh S">SC Oh</name></author><author><name sortKey="Park, Yy" uniqKey="Park Y">YY Park</name></author><author><name sortKey="Park, Es" uniqKey="Park E">ES Park</name></author><author><name sortKey="Lim, Jy" uniqKey="Lim J">JY Lim</name></author><author><name sortKey="Kim, Sm" uniqKey="Kim S">SM Kim</name></author><author><name sortKey="Kim, Sb" uniqKey="Kim S">SB Kim</name></author><author><name sortKey="Kim, J" uniqKey="Kim J">J Kim</name></author><author><name sortKey="Kim, Sc" uniqKey="Kim S">SC Kim</name></author><author><name sortKey="Chu, Is" uniqKey="Chu I">IS Chu</name></author><author><name sortKey="Smith, Jj" uniqKey="Smith J">JJ Smith</name></author><author><name sortKey="Beauchamp, Rd" uniqKey="Beauchamp R">RD Beauchamp</name></author><author><name sortKey="Yeatman, Tj" uniqKey="Yeatman T">TJ Yeatman</name></author><author><name sortKey="Kopetz, S" uniqKey="Kopetz S">S Kopetz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ke, J" uniqKey="Ke J">J Ke</name></author><author><name sortKey="Wu, X" uniqKey="Wu X">X Wu</name></author><author><name sortKey="He, X" uniqKey="He X">X He</name></author><author><name sortKey="Lian, L" uniqKey="Lian L">L Lian</name></author><author><name sortKey="Zou, Y" uniqKey="Zou Y">Y Zou</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author><author><name sortKey="Luo, Y" uniqKey="Luo Y">Y Luo</name></author><author><name sortKey="Wang, L" uniqKey="Wang L">L Wang</name></author><author><name sortKey="Lan, P" uniqKey="Lan P">P Lan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zheng, X" uniqKey="Zheng X">X Zheng</name></author><author><name sortKey="Xie, Q" uniqKey="Xie Q">Q Xie</name></author><author><name sortKey="Li, S" uniqKey="Li S">S Li</name></author><author><name sortKey="Zhang, W" uniqKey="Zhang W">W Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hlavata, I" uniqKey="Hlavata I">I Hlavata</name></author><author><name sortKey="Mohelnikova Duchonova, B" uniqKey="Mohelnikova Duchonova B">B Mohelnikova-Duchonova</name></author><author><name sortKey="Vaclavikova, R" uniqKey="Vaclavikova R">R Vaclavikova</name></author><author><name sortKey="Liska, V" uniqKey="Liska V">V Liska</name></author><author><name sortKey="Pitule, P" uniqKey="Pitule P">P Pitule</name></author><author><name sortKey="Novak, P" uniqKey="Novak P">P Novak</name></author><author><name sortKey="Bruha, J" uniqKey="Bruha J">J Bruha</name></author><author><name sortKey="Vycital, O" uniqKey="Vycital O">O Vycital</name></author><author><name sortKey="Holubec, L" uniqKey="Holubec L">L Holubec</name></author><author><name sortKey="Treska, V" uniqKey="Treska V">V Treska</name></author><author><name sortKey="Vodicka, P" uniqKey="Vodicka P">P Vodicka</name></author><author><name sortKey="Soucek, P" uniqKey="Soucek P">P Soucek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Giraldez, Md" uniqKey="Giraldez M">MD Giraldez</name></author><author><name sortKey="Lozano, Jj" uniqKey="Lozano J">JJ Lozano</name></author><author><name sortKey="Cuatrecasas, M" uniqKey="Cuatrecasas M">M Cuatrecasas</name></author><author><name sortKey="Alonso Espinaco, V" uniqKey="Alonso Espinaco V">V Alonso-Espinaco</name></author><author><name sortKey="Maurel, J" uniqKey="Maurel J">J Maurel</name></author><author><name sortKey="Marmol, M" uniqKey="Marmol M">M Marmol</name></author><author><name sortKey="Horndler, C" uniqKey="Horndler C">C Horndler</name></author><author><name sortKey="Ortego, J" uniqKey="Ortego J">J Ortego</name></author><author><name sortKey="Alonso, V" uniqKey="Alonso V">V Alonso</name></author><author><name sortKey="Escudero, P" uniqKey="Escudero P">P Escudero</name></author><author><name sortKey="Ramirez, G" uniqKey="Ramirez G">G Ramirez</name></author><author><name sortKey="Petry, C" uniqKey="Petry C">C Petry</name></author><author><name sortKey="Lasalvia, L" uniqKey="Lasalvia L">L Lasalvia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kahlert, C" uniqKey="Kahlert C">C Kahlert</name></author><author><name sortKey="Gaitzsch, E" uniqKey="Gaitzsch E">E Gaitzsch</name></author><author><name sortKey="Steinert, G" uniqKey="Steinert G">G Steinert</name></author><author><name sortKey="Mogler, C" uniqKey="Mogler C">C Mogler</name></author><author><name sortKey="Herpel, E" uniqKey="Herpel E">E Herpel</name></author><author><name sortKey="Hoffmeister, M" uniqKey="Hoffmeister M">M Hoffmeister</name></author><author><name sortKey="Jansen, L" uniqKey="Jansen L">L Jansen</name></author><author><name sortKey="Benner, A" uniqKey="Benner A">A Benner</name></author><author><name sortKey="Brenner, H" uniqKey="Brenner H">H Brenner</name></author><author><name sortKey="Chang Claude, J" uniqKey="Chang Claude J">J Chang-Claude</name></author><author><name sortKey="Rahbari, N" uniqKey="Rahbari N">N Rahbari</name></author><author><name sortKey="Schmidt, T" uniqKey="Schmidt T">T Schmidt</name></author><author><name sortKey="Klupp, F" uniqKey="Klupp F">F Klupp</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ishihara, Y" uniqKey="Ishihara Y">Y Ishihara</name></author><author><name sortKey="Matsunaga, K" uniqKey="Matsunaga K">K Matsunaga</name></author><author><name sortKey="Iijima, H" uniqKey="Iijima H">H Iijima</name></author><author><name sortKey="Hasegawa, G" uniqKey="Hasegawa G">G Hasegawa</name></author><author><name sortKey="Suzuki, T" uniqKey="Suzuki T">T Suzuki</name></author><author><name sortKey="Sato, A" uniqKey="Sato A">A Sato</name></author><author><name sortKey="Kobayashi, T" uniqKey="Kobayashi T">T Kobayashi</name></author><author><name sortKey="Yang, M" uniqKey="Yang M">M Yang</name></author><author><name sortKey="Hoffman, Rm" uniqKey="Hoffman R">RM Hoffman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Qiao, E" uniqKey="Qiao E">E Qiao</name></author><author><name sortKey="Ji, M" uniqKey="Ji M">M Ji</name></author><author><name sortKey="Wu, J" uniqKey="Wu J">J Wu</name></author><author><name sortKey="Ma, R" uniqKey="Ma R">R Ma</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="He, Y" uniqKey="He Y">Y He</name></author><author><name sortKey="Zha, Q" uniqKey="Zha Q">Q Zha</name></author><author><name sortKey="Song, X" uniqKey="Song X">X Song</name></author><author><name sortKey="Zhu, Lw" uniqKey="Zhu L">LW Zhu</name></author><author><name sortKey="Tang, J" uniqKey="Tang J">J Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chakraborty, S" uniqKey="Chakraborty S">S Chakraborty</name></author><author><name sortKey="Kanakasabai, S" uniqKey="Kanakasabai S">S Kanakasabai</name></author><author><name sortKey="Bright, Jj" uniqKey="Bright J">JJ Bright</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burger, Pe" uniqKey="Burger P">PE Burger</name></author><author><name sortKey="Gupta, R" uniqKey="Gupta R">R Gupta</name></author><author><name sortKey="Xiong, X" uniqKey="Xiong X">X Xiong</name></author><author><name sortKey="Ontiveros, Cs" uniqKey="Ontiveros C">CS Ontiveros</name></author><author><name sortKey="Salm, Sn" uniqKey="Salm S">SN Salm</name></author><author><name sortKey="Moscatelli, D" uniqKey="Moscatelli D">D Moscatelli</name></author><author><name sortKey="Wilson, El" uniqKey="Wilson E">EL Wilson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ginestier, C" uniqKey="Ginestier C">C Ginestier</name></author><author><name sortKey="Hur, Mh" uniqKey="Hur M">MH Hur</name></author><author><name sortKey="Charafe Jauffret, E" uniqKey="Charafe Jauffret E">E Charafe-Jauffret</name></author><author><name sortKey="Monville, F" uniqKey="Monville F">F Monville</name></author><author><name sortKey="Dutcher, J" uniqKey="Dutcher J">J Dutcher</name></author><author><name sortKey="Brown, M" uniqKey="Brown M">M Brown</name></author><author><name sortKey="Jacquemier, J" uniqKey="Jacquemier J">J Jacquemier</name></author><author><name sortKey="Viens, P" uniqKey="Viens P">P Viens</name></author><author><name sortKey="Kleer, Cg" uniqKey="Kleer C">CG Kleer</name></author><author><name sortKey="Liu, S" uniqKey="Liu S">S Liu</name></author><author><name sortKey="Schott, A" uniqKey="Schott A">A Schott</name></author><author><name sortKey="Hayes, D" uniqKey="Hayes D">D Hayes</name></author><author><name sortKey="Birnbaum, D" uniqKey="Birnbaum D">D Birnbaum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Landen, Cn" uniqKey="Landen C">CN Landen</name></author><author><name sortKey="Goodman, B" uniqKey="Goodman B">B Goodman</name></author><author><name sortKey="Katre, Aa" uniqKey="Katre A">AA Katre</name></author><author><name sortKey="Steg, Ad" uniqKey="Steg A">AD Steg</name></author><author><name sortKey="Nick, Am" uniqKey="Nick A">AM Nick</name></author><author><name sortKey="Stone, Rl" uniqKey="Stone R">RL Stone</name></author><author><name sortKey="Miller, Ld" uniqKey="Miller L">LD Miller</name></author><author><name sortKey="Mejia, Pv" uniqKey="Mejia P">PV Mejia</name></author><author><name sortKey="Jennings, Nb" uniqKey="Jennings N">NB Jennings</name></author><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author><author><name sortKey="Bast, Rc" uniqKey="Bast R">RC Bast</name></author><author><name sortKey="Coleman, Rl" uniqKey="Coleman R">RL Coleman</name></author><author><name sortKey="Lopez Berestein, G" uniqKey="Lopez Berestein G">G Lopez-Berestein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tomita, H" uniqKey="Tomita H">H Tomita</name></author><author><name sortKey="Tanaka, K" uniqKey="Tanaka K">K Tanaka</name></author><author><name sortKey="Tanaka, T" uniqKey="Tanaka T">T Tanaka</name></author><author><name sortKey="Hara, A" uniqKey="Hara A">A Hara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cui, Jy" uniqKey="Cui J">JY Cui</name></author><author><name sortKey="Gunewardena, Ss" uniqKey="Gunewardena S">SS Gunewardena</name></author><author><name sortKey="Rockwell, Ce" uniqKey="Rockwell C">CE Rockwell</name></author><author><name sortKey="Klaassen, Cd" uniqKey="Klaassen C">CD Klaassen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author><author><name sortKey="Venkatesh, M" uniqKey="Venkatesh M">M Venkatesh</name></author><author><name sortKey="Li, H" uniqKey="Li H">H Li</name></author><author><name sortKey="Goetz, R" uniqKey="Goetz R">R Goetz</name></author><author><name sortKey="Mukherjee, S" uniqKey="Mukherjee S">S Mukherjee</name></author><author><name sortKey="Biswas, A" uniqKey="Biswas A">A Biswas</name></author><author><name sortKey="Zhu, L" uniqKey="Zhu L">L Zhu</name></author><author><name sortKey="Kaubisch, A" uniqKey="Kaubisch A">A Kaubisch</name></author><author><name sortKey="Wang, L" uniqKey="Wang L">L Wang</name></author><author><name sortKey="Pullman, J" uniqKey="Pullman J">J Pullman</name></author><author><name sortKey="Whitney, K" uniqKey="Whitney K">K Whitney</name></author><author><name sortKey="Kuro, Om" uniqKey="Kuro O">OM Kuro</name></author><author><name sortKey="Roig, Ai" uniqKey="Roig A">AI Roig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pondugula, Sr" uniqKey="Pondugula S">SR Pondugula</name></author><author><name sortKey="Mani, S" uniqKey="Mani S">S Mani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Staudinger, Jl" uniqKey="Staudinger J">JL Staudinger</name></author><author><name sortKey="Goodwin, B" uniqKey="Goodwin B">B Goodwin</name></author><author><name sortKey="Jones, Sa" uniqKey="Jones S">SA Jones</name></author><author><name sortKey="Hawkins Brown, D" uniqKey="Hawkins Brown D">D Hawkins-Brown</name></author><author><name sortKey="Mackenzie, Ki" uniqKey="Mackenzie K">KI MacKenzie</name></author><author><name sortKey="Latour, A" uniqKey="Latour A">A LaTour</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Klaassen, Cd" uniqKey="Klaassen C">CD Klaassen</name></author><author><name sortKey="Brown, Kk" uniqKey="Brown K">KK Brown</name></author><author><name sortKey="Reinhard, J" uniqKey="Reinhard J">J Reinhard</name></author><author><name sortKey="Willson, Tm" uniqKey="Willson T">TM Willson</name></author><author><name sortKey="Koller, Bh" uniqKey="Koller B">BH Koller</name></author><author><name sortKey="Kliewer, Sa" uniqKey="Kliewer S">SA Kliewer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hirsch, Ha" uniqKey="Hirsch H">HA Hirsch</name></author><author><name sortKey="Iliopoulos, D" uniqKey="Iliopoulos D">D Iliopoulos</name></author><author><name sortKey="Tsichlis, Pn" uniqKey="Tsichlis P">PN Tsichlis</name></author><author><name sortKey="Struhl, K" uniqKey="Struhl K">K Struhl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rausch, V" uniqKey="Rausch V">V Rausch</name></author><author><name sortKey="Liu, L" uniqKey="Liu L">L Liu</name></author><author><name sortKey="Kallifatidis, G" uniqKey="Kallifatidis G">G Kallifatidis</name></author><author><name sortKey="Baumann, B" uniqKey="Baumann B">B Baumann</name></author><author><name sortKey="Mattern, J" uniqKey="Mattern J">J Mattern</name></author><author><name sortKey="Gladkich, J" uniqKey="Gladkich J">J Gladkich</name></author><author><name sortKey="Wirth, T" uniqKey="Wirth T">T Wirth</name></author><author><name sortKey="Schemmer, P" uniqKey="Schemmer P">P Schemmer</name></author><author><name sortKey="Buchler, Mw" uniqKey="Buchler M">MW Buchler</name></author><author><name sortKey="Zoller, M" uniqKey="Zoller M">M Zoller</name></author><author><name sortKey="Salnikov, Av" uniqKey="Salnikov A">AV Salnikov</name></author><author><name sortKey="Herr, I" uniqKey="Herr I">I Herr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Krausova, L" uniqKey="Krausova L">L Krausova</name></author><author><name sortKey="Stejskalova, L" uniqKey="Stejskalova L">L Stejskalova</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author><author><name sortKey="Vrzal, R" uniqKey="Vrzal R">R Vrzal</name></author><author><name sortKey="Dvorak, Z" uniqKey="Dvorak Z">Z Dvorak</name></author><author><name sortKey="Mani, S" uniqKey="Mani S">S Mani</name></author><author><name sortKey="Pavek, P" uniqKey="Pavek P">P Pavek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, C" uniqKey="Zhou C">C Zhou</name></author><author><name sortKey="Poulton, Ej" uniqKey="Poulton E">EJ Poulton</name></author><author><name sortKey="Grun, F" uniqKey="Grun F">F Grun</name></author><author><name sortKey="Bammler, Tk" uniqKey="Bammler T">TK Bammler</name></author><author><name sortKey="Blumberg, B" uniqKey="Blumberg B">B Blumberg</name></author><author><name sortKey="Thummel, Ke" uniqKey="Thummel K">KE Thummel</name></author><author><name sortKey="Eaton, Dl" uniqKey="Eaton D">DL Eaton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bartley, An" uniqKey="Bartley A">AN Bartley</name></author><author><name sortKey="Parikh, N" uniqKey="Parikh N">N Parikh</name></author><author><name sortKey="Hsu, Ch" uniqKey="Hsu C">CH Hsu</name></author><author><name sortKey="Roe, Dj" uniqKey="Roe D">DJ Roe</name></author><author><name sortKey="Buckmeier, Ja" uniqKey="Buckmeier J">JA Buckmeier</name></author><author><name sortKey="Corley, L" uniqKey="Corley L">L Corley</name></author><author><name sortKey="Phipps, Ra" uniqKey="Phipps R">RA Phipps</name></author><author><name sortKey="Gallick, G" uniqKey="Gallick G">G Gallick</name></author><author><name sortKey="Lance, P" uniqKey="Lance P">P Lance</name></author><author><name sortKey="Thompson, Pa" uniqKey="Thompson P">PA Thompson</name></author><author><name sortKey="Hamilton, Sr" uniqKey="Hamilton S">SR Hamilton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carpentino, Je" uniqKey="Carpentino J">JE Carpentino</name></author><author><name sortKey="Hynes, Mj" uniqKey="Hynes M">MJ Hynes</name></author><author><name sortKey="Appelman, Hd" uniqKey="Appelman H">HD Appelman</name></author><author><name sortKey="Zheng, T" uniqKey="Zheng T">T Zheng</name></author><author><name sortKey="Steindler, Da" uniqKey="Steindler D">DA Steindler</name></author><author><name sortKey="Scott, Ew" uniqKey="Scott E">EW Scott</name></author><author><name sortKey="Huang, Eh" uniqKey="Huang E">EH Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Mp" uniqKey="Kim M">MP Kim</name></author><author><name sortKey="Fleming, Jb" uniqKey="Fleming J">JB Fleming</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author><author><name sortKey="Abbruzzese, Jl" uniqKey="Abbruzzese J">JL Abbruzzese</name></author><author><name sortKey="Choi, W" uniqKey="Choi W">W Choi</name></author><author><name sortKey="Kopetz, S" uniqKey="Kopetz S">S Kopetz</name></author><author><name sortKey="Mcconkey, Dj" uniqKey="Mcconkey D">DJ McConkey</name></author><author><name sortKey="Evans, Db" uniqKey="Evans D">DB Evans</name></author><author><name sortKey="Gallick, Ge" uniqKey="Gallick G">GE Gallick</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27448961</article-id><article-id pub-id-type="pmc">5302934</article-id><article-id pub-id-type="publisher-id">10646</article-id><article-id pub-id-type="doi">10.18632/oncotarget.10646</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Pregnane X-receptor promotes stem cell-mediated colon cancer relapse</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Planque</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Rajabi</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grillet</surname><given-names>Fanny</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Finetti</surname><given-names>Pascal</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bertucci</surname><given-names>François</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gironella</surname><given-names>Meritxell</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lozano</surname><given-names>Juan José</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Beucher</surname><given-names>Bertrand</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Giraud</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Garambois</surname><given-names>Véronique</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vincent</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caillo</surname><given-names>Ludovic</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kantar</surname><given-names>Jovana</given-names></name><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pelegrin</surname><given-names>André</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Prudhomme</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="A9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ripoche</surname><given-names>Jérémie</given-names></name><xref ref-type="aff" rid="A9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bourgaux</surname><given-names>Jean François</given-names></name><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ginestier</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="A11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Castells</surname><given-names>Antoni</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hollande</surname><given-names>Frédéric</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pannequin</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pascussi</surname><given-names>Jean Marc</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France</aff><aff id="A2"><sup>2</sup> INSERM U1191, Montpellier, France</aff><aff id="A3"><sup>3</sup> Université Montpellier, Montpellier, France</aff><aff id="A4"><sup>4</sup> Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Marseille, France</aff><aff id="A5"><sup>5</sup> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</aff><aff id="A6"><sup>6</sup> Institut de Recherche en Cancérologie de Montpellier, Montpellier, France</aff><aff id="A7"><sup>7</sup> Department of Pathology, University of Melbourne, Parkville, Australia</aff><aff id="A8"><sup>8</sup> Laboratoire de Biochimie, CHU Carémeau, Nîmes, France</aff><aff id="A9"><sup>9</sup> Service de Chirurgie Digestive, CHU Carémeau, Nîmes, France</aff><aff id="A10"><sup>10</sup> Service d'Hépato-Gastroentérologie, CHU Carémeau, Nîmes, France</aff><aff id="A11"><sup>11</sup> Centre de Recherche en Cancérologie de Marseille, U1068 Inserm, Marseille, France</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Frédéric Hollande,</italic><email>frederic.hollande@unimelb.edu.au</email></corresp><corresp id="cor2"><italic>Jean Marc Pascussi,</italic><email>jean-marc.pascussi@inserm.fr</email></corresp></author-notes><pub-date pub-type="collection"><day>30</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>18</day><month>7</month><year>2016</year></pub-date><volume>7</volume><issue>35</issue><fpage>56558</fpage><lpage>56573</lpage><history><date date-type="received"><day>23</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: © 2016 Planque et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Colorectal cancer lethality usually results from post-treatment relapse in the majority of stage II-IV patients, due to the enhanced resistance of Cancer Stem Cells (CSCs). Here, we show that the nuclear receptor Pregnane X Receptor (PXR, NR1I2), behaves as a key driver of CSC-mediated tumor recurrence. First, PXR is specifically expressed in CSCs, where it drives the expression of genes involved in self-renewal and chemoresistance. Clinically, high levels of PXR correlate with poor recurrence-free survival in a cohort of >200 stage II/III colorectal cancer patients treated with chemotherapy, for whom finding biomarkers of treatment outcome is an urgent clinical need. shRNA silencing of PXR increased the chemo-sensitivity of human colon CSCs, reduced their self-renewal and tumor-initiating potential, and drastically delayed tumor recurrence in mice following chemotherapy. This study uncovers PXR as a key factor for CSC self-renewal and chemoresistance and targeting PXR thus represents a promising strategy to minimize colorectal cancer relapse by selectively sensitizing CSCs to chemotherapy.</p></abstract><kwd-group><kwd>PXR</kwd><kwd>colorectal cancer</kwd><kwd>cancer stem cell</kwd><kwd>tumor recurrence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Colorectal cancer (CRC) is the third most commonly diagnosed cancer, which causes 655,000 deaths annually worldwide [<xref rid="R1" ref-type="bibr">1</xref>]. To this day systemic chemotherapy cocktails (5-fluorouracil (5-FU), irinotecan, and oxaliplatin) that target the bulk population of proliferative tumor cells remain the cornerstone of treatment for advanced CRC [<xref rid="R2" ref-type="bibr">2</xref>]. However, treatment efficiency is severely hampered by the frequent occurrence of drug-resistance and post-treatment tumor recurrence. In recent years, highly tumorigenic sub-populations of cancer cells, named Cancer Stem Cells (CSCs), have been implicated in post-treatment tumor recurrence [<xref rid="R3" ref-type="bibr">3</xref>]. These cells are characterized by the expression of stem cell factors that endow them with stemness properties, such as the ability to self-renew. They are capable of initiating and sustaining tumor growth in serial transplantation assays [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>]. In addition, they are notably characterized by a higher capacity to resist treatments compared to other tumor cells [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>]. Evidence from xenograft models [<xref rid="R8" ref-type="bibr">8</xref>] and human trials [<xref rid="R9" ref-type="bibr">9</xref>] indicate selective enrichment of CSCs in CRC tumors that survive therapy.</p><p>Given that CSCs are the chief culprits in the failure of current therapies, it is important to identify innovative approaches that target them to improve clinical outcomes for cancer patients. To date, most strategies aim to inhibit CSC self-renewal or to induce their differentiation [<xref rid="R10" ref-type="bibr">10</xref>]. However, these phenotypic traits are shared by healthy adult stem cells, leading to specific concerns about potential side effects. An alternative CRC therapy would be to sensitize CSCs to current therapies, but the precise mechanism underlying the higher drug resistance of CSCs remains unclear. Multiple parameters have been proposed to be involved in CSC drug resistance, including slow proliferation, increased resistance to DNA damage, activation of anti-apoptosis mechanisms, but also expression of multidrug transporters such as ATP-binding cassette G2 (ABCG2 [<xref rid="R11" ref-type="bibr">11</xref>]) and of drug metabolizing enzymes including aldehyde dehydrogenase 1A1 (ALDH1A1 [<xref rid="R12" ref-type="bibr">12</xref>]) and the cytochrome P450 CYP3A4 [<xref rid="R13" ref-type="bibr">13</xref>]. Accordingly, flow cytometry strategies based on ABCG2 expression (Side Population, SP) and ALDH-activity (Aldefluor-‘bright’ cells or ALDH<sup>br</sup>) have been used to identify CSCs in various types of solid tumors including CRC [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>]. SP cells and ALDH<sup>br</sup> cells are also characterized by an enhanced chemoresistance to various cytotoxics [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R8" ref-type="bibr">8</xref>]. Consequently, these populations are enriched following chemotherapy [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R16" ref-type="bibr">16</xref>].</p><p>We previously reported that the orphan nuclear receptor PXR (Pregnane X Receptor, NR1I2), a key regulator of xenobiotic metabolism in the liver [<xref rid="R18" ref-type="bibr">18</xref>], increased irinotecan resistance in CRC cell lines [<xref rid="R19" ref-type="bibr">19</xref>]. Since PXR has been previously described to regulate CYP3A4 gene expression in human hepatocytes [<xref rid="R18" ref-type="bibr">18</xref>], and Aldh1a1 and Abcg2 genes in mice [<xref rid="R20" ref-type="bibr">20</xref>] and porcine [<xref rid="R21" ref-type="bibr">21</xref>] tissues respectively, we hypothesized that PXR may participate in the intrinsic chemoresistance of CSCs. Here, we demonstrate that PXR expression and activity are indeed highly restricted to CSCs, where it drives the expression of a large network of genes that are instrumental for CSC chemoresistance <italic>in vitro</italic> and <italic>in vivo</italic>. Furthermore, we observed that PXR and its targets form a prognostic indicator for CRC relapse. These results pinpoint PXR as a clinically druggable Achilles' heel for CSCs in colorectal and potentially also in other cancers.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>PXR expression and activity define chemoresistant colon cancer stem cells</title><p>We compared PXR expression in CSCs <italic>versus</italic> non-CSCs by using enrichment of self-renewing cells <italic>(i.e</italic>. spheroids passaging). Previous studies showed that under defined conditions, CRC cells maintained as floating spheroids display enhanced expression of cancer stem cell markers, increased self-renewal and resistance to chemotherapeutic drugs [<xref rid="R16" ref-type="bibr">16</xref>]. We confirmed those observations in patient-derived CRC cells (CRC1) maintained as spheroids (Sphe) compared to cells maintained in adherent conditions and exposed to serum-containing medium (2D). As shown, cells isolated from spheroids had a higher proportion of cells with ALDH activity (Aldefluor positive (‘bright’) cells, ALDH<sup>br</sup>, Figure <xref ref-type="fig" rid="F1">1a</xref>). In addition, they had enhanced spheroid-forming efficiency (Figure <xref ref-type="fig" rid="F1">1b</xref>), a widely used <italic>in vitro</italic> assay for CSC quantification [<xref rid="R7" ref-type="bibr">7</xref>], calculated as the percentage of seeded cells that gave rise to a spheroid. Moreover, cells maintained as spheroids had a greater resistance to a combination of 5-FU and SN38 (hereafter named “Firi” as SN38 is the active metabolite of irinotecan), when compared to the same cells maintained as adherent monolayers (≈2-fold increase in EC<sub>50</sub>, p<0.01; Figure <xref ref-type="fig" rid="F1">1c</xref>). RT-qPCR analyses revealed the higher expression of PXR in spheroids compared to 2D conditions as well as an enriched expression of colon CSCs markers (ALDH1A1, Oct-4 [<xref rid="R22" ref-type="bibr">22</xref>] and LGR5 [<xref rid="R23" ref-type="bibr">23</xref>]) and PXR target genes (CYP3A4 and ABCG2) (Figure <xref ref-type="fig" rid="F1">1d</xref>). Similar results were obtained in other tested human CRC cell lines (Figure <xref ref-type="fig" rid="F1">1e</xref>) and patient-derived CRC cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1a</xref>). In addition, both PXR protein expression and PXR transcriptional activity, measured using a PXR luciferase reporter gene [<xref rid="R24" ref-type="bibr">24</xref>], were higher in spheroids compared to adherent (2D) conditions (Figure <xref ref-type="fig" rid="F1">1f, 1g</xref>). Finally, serial passaging of spheroids (passages 1 to 8, i.e. S1 to S8) resulted in the gradual and concomitant enrichment of spheroid-forming efficiency, of ALDH<sup>br</sup> cell percentage and of mRNA expression of CSC markers, correlating tightly with the up regulation of PXR (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1b-S1d</xref>). Taken together these findings indicate that PXR is preferentially expressed and active in self-renewing colon CSCs.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>PXR expression is increased in colorectal spheroid models</title><p><bold>a.</bold> Percentage of ALDH<sup>br</sup> cells, and <bold>b.</bold> percentage of Sphere-Forming Cells of patient-derived CRC cells (CRC1) grown as adherent (2D) or colonosphere (Sphe) cultures. <bold>c.</bold> Percentage of CRC1 surviving cells 72 hours after exposure to the indicated concentrations of Firi (1X=50μM 5-FU + 500nM SN38). Data are expressed as mean ± SEM of 3 experiments, and half maximal effective concentrations (EC<sub>50</sub>) are indicated. <bold>d.</bold> RT-qPCR analyses of mRNA expression for PXR, PXR target and CSC marker genes in CRC1 cells maintained as Spheroids compared to 2D conditions (F.I., Fold Induction). <bold>e.</bold> RT-qPCR quantification of PXR mRNA in CRC cell lines maintained as Spheroids compared to 2D conditions. <italic>d,e,:</italic> Data are expressed as mean ± SEM (n>3) and reported as fold change compared to cells grown in 2D conditions. <bold>f.</bold> Western-blot analysis of PXR expression in CRC1 cells maintained as Spheroids compared to 2D conditions. Data are expressed as mean ± SEM (n=3) of PXR/GAPDH ratio. <bold>g.</bold> PXR transcriptional activity was determined in CRC1 cells after transfection with luciferase reporter plasmids. Data are expressed as mean ± SEM (n=3) of luciferase/β-Galactosidase ratio, normalized to 2D conditions. *, p<0.05; **, p<0.005.</p></caption><graphic xlink:href="oncotarget-07-56558-g001"></graphic></fig><p>We then isolated CSCs using fluorescence-activated cell sorting based on the activity of Aldefluor. Aldefluor activity and ALDH1A1 gene expression have been described as colon CSC markers [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R25" ref-type="bibr">25</xref>] and the latter is a regulator of chemoresistance [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>] and cell renewal [<xref rid="R28" ref-type="bibr">28</xref>]. First, we confirmed that the enhanced Aldefluor activity (ALDH<sup>br</sup>, Figure <xref ref-type="fig" rid="F2">2a</xref>) was indeed associated with the specific expression of the ALDH1A1 mRNA isoform in CRC cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2a, S2b</xref>). CRC1 ALDH<sup>br</sup> cells had greater spheroid-forming efficiency (Figure <xref ref-type="fig" rid="F2">2b</xref>) and they were more resistant to Firi treatment (≈6.8-fold higher EC<sub>50</sub>, p<0.01; Figure <xref ref-type="fig" rid="F2">2c</xref>) than ALDH<sup>lo</sup> cells. As shown on Figure <xref ref-type="fig" rid="F2">2d</xref>, PXR mRNA was strongly enriched in the ALDH<sup>br</sup> population. Similar results were obtained in other tested CRC cell lines (Figures <xref ref-type="fig" rid="F2">2e</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1b</xref>). PXR protein expression was only detected in the ALDH<sup>br</sup> population (Figure <xref ref-type="fig" rid="F2">2f</xref>), which expectedly had higher ALDH1A1 mRNA and protein levels (Figures <xref ref-type="fig" rid="F2">2d, 2f</xref>, and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2a, S2b</xref>). In addition, luciferase reporter genes for PXR transcriptional activity were specifically increased in ALDH<sup>br</sup> cells (Figures <xref ref-type="fig" rid="F2">2g</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2c, S2d</xref>), indicating that PXR is preferentially expressed and active in colon ALDH<sup>br</sup> cells.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>PXR expression is increased in colorectal ALDH<sup>br</sup> CSCs</title><p><bold>a.</bold> Aldefluor assay and gates used for CRC1 cell-sorting. The ALDH inhibitor DEAB was added to identify ALDH-positive (ALDH<sup>br</sup>) cells. <bold>b.</bold> Percentage of sphere-forming cells of the ALDH<sup>br</sup> and ALDH<sup>lo</sup> populations. <bold>c.</bold> Percentage of surviving cells, 72 hours after exposure of ALDH<sup>br</sup> and ALDH<sup>lo</sup> cells to the indicated concentrations of Firi (1X=50μM 5-FU + 500nM SN38). Data are expressed as mean ± SEM of 3 experiments, and half maximal effective concentrations (EC<sub>50</sub>) are indicated. <bold>d.</bold> RT-qPCR analyses of mRNA expression for PXR, PXR targets and CSC marker genes in the ALDH<sup>br</sup> compared to the ALDH<sup>lo</sup> population (F.I., Fold Induction). <bold>e.</bold> RT-qPCR quantification of PXR mRNA in ALDH<sup>br</sup> and ALDH<sup>lo</sup> cells from CRC cell lines. <italic>d,e:</italic> Data are expressed as mean ± SEM (n=3) and reported as fold change compared to ALDH<sup>lo</sup> cells. <bold>f.</bold> ALDH1A1, PXR, GAPDH and β-ACTIN protein expression in unsorted (NS), ALDH<sup>lo</sup> and ALDH<sup>br</sup> CRC1 cells. <bold>g.</bold> PXR transcriptional activity was determined in ALDH<sup>lo</sup> and ALDH<sup>br</sup> CRC1 cells 24 hours after transfection with luciferase reporter plasmids. Data are expressed as mean ± SEM (n=3) of luciferase/β-Galactosidase ratio. *, p<0.05; **, p<0.005.</p></caption><graphic xlink:href="oncotarget-07-56558-g002"></graphic></fig><p>To validate the preferential expression and activity of PXR in chemoresistant CSCs, we infected T84 cells with a GFP-tagged PXR-driven promoter (CYP3A4eGFP) to selectively sort cells according to their PXR activity level (Figure <xref ref-type="fig" rid="F3">3a</xref>); cells transduced with an EIF1α -driven eGFP construct were used as control. We first validated the reporter system by comparing the expression of PXR and its target genes in cell populations sorted according to their GFP expression level. Cells with high PXR activity (i.e. CYP3A4eGFP<sup>br</sup>) had higher PXR, CYP3A4 and ABCG2 mRNA expression (Figure <xref ref-type="fig" rid="F3">3b</xref>). Furthermore, CYP3A4eGFP<sup>br</sup> cells had enhanced expression of colon CSC markers such as ALDH1A1, Oct-4 and LGR5. In addition, CYP3A4eGFP<sup>br</sup> cells had higher resistance towards Firi treatment (Figure <xref ref-type="fig" rid="F3">3c</xref>). Finally, CYP3A4eGFP<sup>br</sup> cells had higher sphere-forming efficiency (Figure <xref ref-type="fig" rid="F3">3d</xref>) and a ten-fold higher stem cell frequency (as calculated according to Hu et al. [<xref rid="R29" ref-type="bibr">29</xref>]) (1/9±3 for CYP3A4<sup>br</sup> cells vs 1/94±32 for CYP3A4<sup>lo</sup> cells, p=0.002) compared to CYP3A4eGFP<sup>lo</sup> cells. Accordingly, flow cytometry analyses showed a specific increase of cells with strong PXR activity after CSC selection, by spheroid passaging or Firi treatment (Figure <xref ref-type="fig" rid="F3">3e</xref>). Together these data demonstrate that PXR transcriptional activity tracks chemo-resistant CSCs.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>PXR transcriptional activity marks chemoresistant CSCs</title><p><bold>a.</bold> Flow cytometry profiles of EIF1α-eGFP and CYP3A4-eGFP infected T84 cells and regions used for cell-sorting. NT= Non infected, Lo=GFP low, Br=GFP bright. <bold>b.</bold> RT-qPCR analyses of PXR, PXR target and CSC marker gene mRNA expression in <italic>Br</italic> and <italic>Lo</italic> populations compared to EIF1α-GFP low cells (F.I., Fold Induction). Data are expressed as mean ± SEM (n=3). <bold>c.</bold> Percentage of surviving cells, 72 hours after exposure of sorted cells to the indicated dilutions of Firi (1X=50μM 5-FU + 500nM SN38). Data are expressed as mean ± SEM (n=4). <bold>d.</bold> Percentage of sphere-forming cells for <italic>Br</italic> and <italic>Lo</italic> populations. a,b,c: <italic>#</italic>: p<0.05 compared to <italic>Lo</italic> cells for each GFP construct, <italic>$</italic>: p<0.05 compared to EIF1α-GFP Br cells. <bold>e.</bold> Representative flow cytometry profiles of EIF1α-eGFP- and CYP3A4-eGFP infected cells before (2D NT) or after 72h of Firi (50μM 5-FU + 500nM SN38) treatment followed by 2 days of recovery without treatment (2D FIRI) or maintained as colonospheres (Sphe). The fold increase in GFP <italic>Br</italic> percentage induced by Firi (2D FIRI/2D NT) or colonosphere conditions (Sphe/2D NT) are indicated for each GFP construct as mean ± SEM (n>3). *, p<0.05; **, p<0.005.</p></caption><graphic xlink:href="oncotarget-07-56558-g003"></graphic></fig></sec><sec id="s2_2"><title>PXR regulates a large network of CSC resistance genes and of poor prognosis factors in colon cancer patients treated with chemotherapy</title><p>Having established the preferential expression and activity of PXR in colon CSCs, we then directly assessed the impact of PXR down-regulation on both chemoresistance and mRNA expression profile of patient-derived ALDH<sup>br</sup> cells transfected with PXR siRNA (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S1</xref> for siRNA sequences). First, we observed that ALDH<sup>br</sup> cell survival was significantly decreased after transfection with an efficient siRNA sequence decreasing PXR expression (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S5a</xref> for validation): ALDH<sup>br</sup> siPXR EC<sub>50</sub>=0.40 compared to ALDH<sup>br</sup> siβGAL EC<sub>50</sub>=0.83 (p<0.01, Figure <xref ref-type="fig" rid="F4">4a</xref>). Microarray experiments showed that, 48 hours after transfection, the expression of 374 genes was significantly altered by PXR down-regulation in ALDH<sup>br</sup> cells (<xref ref-type="supplementary-material" rid="SD2">Supplementary Table S2</xref> and Figure <xref ref-type="fig" rid="F4">4b</xref>). Notably, PXR-depletion led to the down-regulation of CSC markers such as ALDH1A1 [<xref rid="R12" ref-type="bibr">12</xref>], OLFM4 [<xref rid="R30" ref-type="bibr">30</xref>], and LRIG-1 [<xref rid="R31" ref-type="bibr">31</xref>] and the up-regulation of differentiation markers such as MUC2 (goblet cells) and FABP1 (enterocytes). A Gene Ontology analysis highlighted that PXR depletion in ALDH<sup>br</sup> cells down-regulates the DNA damage sensor and repair machinery (known to help CSCs to overcome many standard anticancer treatments [<xref rid="R32" ref-type="bibr">32</xref>]), while it promotes the expression of genes involved in apoptosis and cell death (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S3</xref>). GSEA analyses based on a clinical study describing outcome-related gene signatures in groups of patients homogeneously treated with 5-FU-based chemotherapy [<xref rid="R33" ref-type="bibr">33</xref>], showed that down-regulated genes in ALDH<sup>br</sup> cells, following PXR depletion, were specifically enriched in a poor progression-free survival signature. Conversely, genes that were up-regulated in PXR-depleted cells were enriched in the good-prognosis signature (Figure <xref ref-type="fig" rid="F4">4c</xref>). Similar results were observed after PXR gain-of function in two different LS174T clones (i.e. LS PXR2 and LS PXR6; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4a</xref>) in which microarray (<xref ref-type="supplementary-material" rid="SD3">Supplementary Table S3</xref>) and RT-qPCR validation analyses (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4b</xref>) confirmed that over-expression of PXR regulates the expression of multiple colon CSC markers (ALDH1A1, ABCG2, CYP3A4, CD24 [<xref rid="R34" ref-type="bibr">34</xref>], CXCR4 [<xref rid="R35" ref-type="bibr">35</xref>], LRIG-1 and OLFM4) and prognostic markers for colorectal tumor recurrence (ABCC6 [<xref rid="R36" ref-type="bibr">36</xref>] and S100A10 [<xref rid="R37" ref-type="bibr">37</xref>]). Again, GSEA analyses showed that genes with significantly higher expression levels in LS PXR2 and LS PXR6 cells were specifically enriched in the poor-prognosis signature [<xref rid="R33" ref-type="bibr">33</xref>] (Figure <xref ref-type="fig" rid="F4">4d</xref>). Together these results indicate that PXR controls the expression of a large gene network associated with CSC phenotype and post-chemotherapy tumour recurrence.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>PXR regulates a large network of key CSC chemoresistance genes</title><p><bold>a.</bold> Percentage of surviving cells, 48 hours after exposure of cells to the indicated concentrations of Firi (1X=50μM 5-FU + 500nM SN38). ALDH<sup>br</sup> CRC1 cells were first transfected with or without 100nM of control (siβGAL) or PXR-specific (siPXR-1334) siRNA. Data are expressed as mean ± SEM (n=3). <bold>b.</bold> Hierarchical clustering of 6 samples and 374 genes, differentially expressed between PXR siRNA (siPXR) and control siβGAL-transfected ALDH<sup>br</sup> CRC1 cells. Each row represents a gene and each column represents a sample. <bold>c,d.</bold> Gene set enrichment analyses (GSEA) were used to interrogate the similarity of genes that were differentially expressed in the microarray experiments after loss- (c) or gain-of PXR (d) function, to signatures of patient prognosis (Oh, S.C., et al. Gut 61, 1291-1298 (2012)). <italic>c:</italic> genes induced by siRNA-mediated PXR depletion in ALDHbr cells “Up siPXR vs. siβGAL” or decreased by PXR depletion “Down siPXR vs. siβGAL”. <italic>d:</italic> PXR-overexpressing LS174T clones 2&6 versus LS174T control.</p></caption><graphic xlink:href="oncotarget-07-56558-g004"></graphic></fig><p>Since ALDH1A1 appeared as one of the top-ranked differentially regulated genes after PXR up-regulation or inhibition (<xref ref-type="supplementary-material" rid="SD2">Supplementary Tables S2</xref>&<xref ref-type="supplementary-material" rid="SD3">S3</xref>) and has been described as key CSC marker [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R25" ref-type="bibr">25</xref>] and a poor prognosis factor in colon cancer patients [<xref rid="R38" ref-type="bibr">38</xref>], we focused our attention on its putative regulation by PXR. First, gain- and loss-of function in LS174T cells confirmed that the expression of ALDH1A1 mRNA and protein was positively regulated by PXR (Figure <xref ref-type="fig" rid="F5">5a, 5b</xref>). In addition, the proportion of ALDH<sup>br</sup> cells was enhanced in PXR-overexpressing cells and strongly decreased upon PXR down regulation by shRNA (Figure <xref ref-type="fig" rid="F5">5c</xref>). Similar results were obtained in the T84 CRC cell line (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4c, S4d, S4e</xref>). Experiments using different shRNA sequences leading to the specific down-regulation of PXR expression or rescue experiment confirmed the direct involvement of PXR on ALDH1A1 and Aldefluor activity level (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S5</xref>). To assess the clinical relevance of correlation between PXR and ALDH expression, we compared PXR and ALDH1A1 mRNA expression in human samples. As shown, PXR and ALDH1A1 were significantly correlated in primary tumor samples from stage II & III CCR patients (n=78) and in CRC liver metastatic samples (n=12) (Figure <xref ref-type="fig" rid="F5">5d</xref>). In addition, we attempted to determine whether PXR expression was correlated with clinical outcome in homogenous groups of chemotherapy-treated colorectal cancer patients. We first performed a Kaplan-Meier analysis of PXR mRNA expression in 5-FU-treated stage II/III CRC patient cohort [<xref rid="R37" ref-type="bibr">37</xref>]. We found that patients bearing tumors with high PXR expression had a significantly lower probability of disease-free survival, indicating that high PXR is associated with poor prognosis in stage II/III colon cancer patients treated with 5-FU-based chemotherapy (n=213; p=0.0369; Figure <xref ref-type="fig" rid="F5">5e</xref>). This effect was even more markedly increased when we analysed the outcome for stage II patients only (n=81; p=0.0089), for whom finding biomarkers of treatment outcome is an urgent clinical need. Similar results were obtained by using RPLO (Figure <xref ref-type="fig" rid="F5">5e</xref>) or GAPDH (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S6</xref>) as reference gene. These results clearly demonstrated that elevated PXR expression in CCR patients is positively correlated with a higher recurrence frequency, an outcome that is often driven by the persistence of chemoresistant cancer stem cells.</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>PXR mRNA expression correlates with ALDH1A1 expression and is a poor prognosis factor in colon cancer patients</title><p><bold>a.</bold> RT-qPCR analyses of PXR and ALDH1A1 mRNA expression, <bold>b.</bold> detection of PXR, ALDH1A1 and GAPDH protein expression by Western blotting after loss- (shPXR) or gain of PXR expression (PXR2). <italic>a:</italic> Data are expressed as mean ± SEM (n≥3) compared to LS174T control cells (shLUC) (F.I., Fold Induction). <italic>b:</italic> N.E.= nuclear extracts, C.E.= cytosolic extracts. <bold>c.</bold> Quantification of ALDH activity using the Aldefluor assay. Percentages of ALDH<sup>br</sup> cells are indicated in inset boxes. <bold>d.</bold> Correlation between PXR and ALDH1A1 mRNA expression in CRC primary tumors of stage II or III patients treated with 5-FU-based chemotherapy (n=78) or in human liver metastasis samples (n=12) obtained from patients with metastatic colorectal disease. <bold>e.</bold> Kaplan-Meier estimates of the probability of resting free from tumor recurrence, according to PXR expression level in CRC primary tumors of stage II & III (upper panel), or stage II (lower panel) patients treated with 5-FU-based chemotherapy. PXR expression was normalized according to RPLO mRNA expression. Patients with low PXR gene expression are depicted in blue and patients with high PXR gene expression in red. <italic>p</italic> value from the likelihood ratio test is shown in each case.</p></caption><graphic xlink:href="oncotarget-07-56558-g005"></graphic></fig></sec><sec id="s2_3"><title>PXR knockdown increases recurrence-free survival in mouse xenograft models</title><p>To study the relationship between PXR and CSCs chemoresistance, we established spheroid cultures from patient-derived colorectal tumor samples (CRC1) and infected these cells with a lentivirus allowing the stable expression of small hairpin RNAs targeted against PXR (shPXR) or a control (shLUC). A significant down-regulation of PXR and PXR-regulated gene mRNAs was observed in shPXR-expressing spheroids (Figure <xref ref-type="fig" rid="F6">6a</xref>). PXR depletion reduced both the ALDH<sup>br</sup> cell population (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S7</xref>) and sphere-forming potential (Figure <xref ref-type="fig" rid="F6">6b</xref>) and these effects were strongly amplified following serial spheroid passaging. To determine the impact of PXR on CSC chemoresistance and post-treatment relapse, we generated tumor xenografts by subcutaneously injecting 15,000 PXR-deficient (shPXR) or control (shLUC) cells from spheroids into nude mice (n=18/group). Twenty days after injection, mice were randomized and received either vehicle or a Folfiri regimen (90mg/kg leucovorin, 50mg/kg 5-FU and 30mg/kg irinotecan, twice a week from day 23 to 45) designed to induce tumor regression [<xref rid="R39" ref-type="bibr">39</xref>]. Tumor growth was noticeably slower in shPXR group compared to shLUC control group in absence of treatment and tumor stasis upon Folfiri treatment was detected in both groups (Figure <xref ref-type="fig" rid="F6">6c</xref>). Three days after treatment cessation (day 48), six mice from the vehicle- and Folfiri-treated groups were sacrificed for subsequent analysis, while tumor growth and post-treatment relapse were monitored in the remaining mice. Recurrence was clearly noticeable from 3 weeks post-treatment (day 69) in shLUC control group, which had a ≈2-fold accelerated growth rate compared to untreated tumors. In contrast, the growth rate of shPXR tumors did not increase after Folfiri treatment (Figure <xref ref-type="fig" rid="F6">6c</xref>) and their recurrence was strongly delayed (Log-Rank Mantel-Cox test p=0.029; Figure <xref ref-type="fig" rid="F6">6d</xref>). Thus PXR depletion efficiently prolongs progression-free survival following chemotherapy. Finally, to determine whether PXR down-regulation affected the <italic>in vivo</italic> tumor-initiating potential of Folfiri-resistant tumor cells, we subcutaneously transplanted 1,500 cells obtained from residual tumors collected three days after treatment completion (day 48) into new nude mice (Figure <xref ref-type="fig" rid="F6">6e</xref>). Cells isolated from Folfiri-treated shLuc control tumors induced the rapid formation of second-generation tumors in all grafted animals. In contrast, tumor growth rate was much lower in mice injected with cells isolated from Folfiri-treated shPXR tumors and tumor incidence was strongly delayed (Log Rank Mantel-Cox test p=0.026; Figure <xref ref-type="fig" rid="F6">6f</xref>). These results clearly indicate that shRNA silencing of PXR delays tumor relapse and affects <italic>in vivo</italic> tumor–initiating potential of CRC cells following chemotherapy.</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Knock-down of PXR decreases CSC-self renewal and improves recurrence free survival in mouse xenograft models</title><p><bold>a.</bold> RT-qPCR analyses of PXR and PXR target gene mRNA expression in CRC1 cells expressing PXR-shRNA (shPXR-1334). Data are expressed as mean ± SEM (n=3) compared to control CRC1 cells (CRC1 shLUC). *, p<0.05; **, p<0.005. <bold>b.</bold> Percentage of sphere-forming cells of shLuc and shPXR CRC1 colon cancer cells maintained as first-generation spheres (S1) or after 4-8 passages (S4-S8). Data are expressed as mean ± SEM (n=3). <bold>c.</bold> Tumor volume over time after subcutaneous injection of 15,000 shLuc or shPXR CRC1 colon cancer cells isolated from colonospheres (18mice/group). Mice were randomized once tumors reached a volume of 100 mm<sup>3</sup> (day 20). Three days after randomization, one group (6 mice/group) was treated twice weekly for 4 weeks with vehicle or with Folfiri. At day 48, three days after the end of treatment, 6 mice per group were sacrificed and the remaining ones from the Folfiri-treated groups (6 mice/group) were kept for 7 weeks without treatment to further monitor tumor growth. Data are expressed as mean ± SEM of the fold-increase (F.I.) compared to the corresponding tumor volume at day 20. <bold>d.</bold> Kaplan–Meier survival plots after treatment cessation representing the time for animals to reach the endpoint tumor size of 1000 mm3. <bold>e.</bold> Tumor volume over time after subcutaneous injection of tumor cells obtained at day 48 from xenograft tumors shown in <italic>(c)</italic>, processed for cell dissociation and sub-cutaneously re-implantated in immunodeficient mice (6 mice/group, 1,500 live (7-AAD-negative) cells/mouse). <bold>f.</bold> Survival plots after secondary injection of residual Folfiri-treated shLUC or shPXR cells.</p></caption><graphic xlink:href="oncotarget-07-56558-g006"></graphic></fig></sec><sec id="s2_4"><title>PXR depletion impairs chemotherapy-induced enrichment of tumorigenic CSCs <italic>in vivo</italic></title><p>To understand the cellular mechanism involved in the tumor relapse of CRC cells following chemotherapy, we analyzed the reservoir of CSCs from tumors, collected three days after treatment cessation (Figure <xref ref-type="fig" rid="F6">6c</xref>, day 48). We first analyzed the frequency of CSCs from tumors collected at day 48 from untreated and folfiri-treated mice. In agreement with the literature [<xref rid="R8" ref-type="bibr">8</xref>], we found a significant increase of spheroid-forming efficiency after Folfiri treatment in control tumors (Figure <xref ref-type="fig" rid="F7">7a</xref>), suggesting that chemotherapy increased the proportion of CSCs whilst eliminating the more differentiated and proliferative tumor cells. However, this selection of CSCs was completely abolished in shPXR-derived tumors. Indeed, spheroid-forming efficiency was even lower in shPXR-derived tumors cells following chemotherapy compared to untreated shPXR or shLUC tumor cells, therefore the down-regulation of PXR completely prevents chemotherapy-induced CSC enrichment. Accordingly, while the proportion of ALDH<sup>br</sup> cells was significantly increased in Folfiri-treated control tumors, this enrichment was completely impaired in tumors derived from Folfiri-treated shPXR group (Figure <xref ref-type="fig" rid="F7">7b</xref>). Moreover, ALDH1A1-positive cells were barely detectable by immunohistochemistry in sections of Folfiri-treated tumor xenografts in the shPXR group compared to control group (Figure <xref ref-type="fig" rid="F7">7c</xref>). In addition, RT-qPCR revealed a large increase of PXR and CSC gene marker (ALDH1A1, Oct-4 and LGR5) mRNA expression after Folfiri treatment of control tumors (Figure <xref ref-type="fig" rid="F7">7d</xref>). These increases were severely impaired in shPXR tumors. Comparable results were obtained <italic>in vitro</italic> in patient-derived cells (CRC1) or in the LS174T cell line (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S8</xref>) treated with a combination of 5FU and SN38. These results suggest that PXR signaling plays an instrumental role in CSC resistance and that PXR inhibition minimizes the clinically problematic enrichment of these cells in response to chemotherapy.</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>PXR depletion impairs chemotherapy-induced enrichment of PXR and CSC markers <italic>in vivo</italic></title><p>Tumor samples from mice sacrificed at day 48 (see Figure <xref ref-type="fig" rid="F6">6</xref>c) were processed for cell dissociation and, live (7-AAD-negative) tumor cells were further analyzed for their <bold>a.</bold> ability to initiate sphere formation <italic>in vitro</italic> and <bold>b.</bold> Aldefluor activity (% of ALDH<sup>br</sup> cells). Data are expressed as mean±SEM. “<italic>a</italic>”, p<0.05 compared to non-treated shLUC tumors and “<italic>b</italic>”, p<0.05 compared to Folfiri-treated shLuc tumors. <bold>c.</bold> Hematoxylin/Eosin and immunostaining of Folfiri-treated shLuc and shPXR paraffin-embedded tumor sections (day 48) using antibodies directed against human ALDH1A (α-huALDH1A, detecting ALDH1A1 protein [<xref rid="R54" ref-type="bibr">54</xref>–<xref rid="R56" ref-type="bibr">56</xref>]) or human mitochondria (α-huMitoch). Ratios of ALDH1A/human mitochondria-stained areas on tumor sections (n=4/group) are presented below. Data are expressed as mean±SEM. **, p<0.005 <bold>d.</bold> Expression of the indicated mRNAs was quantified by RT-qPCR on cells isolated from dissociated tumors (day 48) of non-treated or Folfiri-treated mice. Data are expressed as mean±SEM. “<italic>a</italic>”, p<0.05 compared to non-treated shLUC tumors and “<italic>b</italic>”, p<0.05 compared to Folfiri-treated shLuc tumors.</p></caption><graphic xlink:href="oncotarget-07-56558-g007"></graphic></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>PXR is a nuclear receptor whose downstream target genes are involved in the production of phase I and II metabolic enzymes and phase III drug transporters. PXR activation has been implicated in poor response of cancer cells [<xref rid="R40" ref-type="bibr">40</xref>]. Here we show that the activity of this receptor is largely restricted to the minority self-renewing cell-subpopulation of tumors and that it is responsible for the ability of cancer stem cells to successfully withstand sustained chemotoxic aggression and this drives post-treatment tumor recurrence. First, we observed that PXR expression is higher in CSC-enriched tumor cells. PXR expression was enriched during spheroid passaging (Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1</xref>), after cell sorting using Aldefluor activity (Figures <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>) and also after drug selection in several CCR cell lines and patient-derived cells (Figures <xref ref-type="fig" rid="F7">7</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S8, S9</xref> and <xref ref-type="supplementary-material" rid="SD1">S10</xref>). In addition, CRC cells with enhanced PXR transcriptional activity had increased expression of CSC markers, self-renewal and chemoresistance (Figure <xref ref-type="fig" rid="F3">3</xref>). These results are in agreement with the fact that, PXR was one of the most overexpressed nuclear receptors in human glioma stem cells compared to glioma cells [<xref rid="R41" ref-type="bibr">41</xref>].</p><p>By using both gain- and loss- of function approaches, we show that PXR drives the expression of a large number of genes that promote several hallmarks of cancer stem cells, such as chemoresistance, DNA repair and self-renewal (<xref ref-type="supplementary-material" rid="SD2">Supplementary Tables S2</xref> and <xref ref-type="supplementary-material" rid="SD3">S3</xref>). Notably, we observed that PXR controls the expression of genes that were previously reported to confer CSC chemoresistance or to have a negative impact on disease-free survival in colon cancer patients, including ABCG2, ABCC6, ALDH1A1, CYP3A4, or S100A10. These observations were corroborated by our observation that stage II and III CRC patients with high PXR expression have a lower probability of disease-free survival after chemotherapy (Figures <xref ref-type="fig" rid="F5">5</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S6</xref>), while GSEA analyses showed that PXR target genes are associated with a poor-prognosis molecular signature in colorectal cancer patients (Figure <xref ref-type="fig" rid="F4">4</xref>). These data strongly suggest that PXR is an upstream molecular switch in CSCs that drives a network of key downstream targets that enable them to resist treatment. PXR may promote the adaptation of CSCs to their environment by providing them with a multi-faceted arsenal that includes an enhanced capacity to resist cell death and chemotoxic insult and thus the ability to self-renew and maintain their stemness potential.</p><p>We demonstrate that PXR down-regulation decreased CSCs chemoresistance (Figure <xref ref-type="fig" rid="F4">4a</xref>) and chemotherapy-induced CSC enrichment and it also significantly delayed tumor relapse after Folfiri treatment of xenografted animals (Figure <xref ref-type="fig" rid="F6">6</xref>). In addition, the tumor-initiating ability of residual tumor cells and the proportion of CSCs found in tumor xenografts at the end of Folfiri treatment were strongly decreased in PXR knockdowns (Figure <xref ref-type="fig" rid="F6">6</xref>). These observations imply that PXR may represent a key target to improve the efficiency of conventional chemotherapy through the sensitization of CSCs and counteract the selection/emergence of chemoresistant CSCs (Figure <xref ref-type="fig" rid="F8">8</xref>). The potential implications of these results are far-reaching as post-treatment relapse is one of the major issues hampering clinical managements of CRC.</p><fig id="F8" orientation="portrait" position="float"><label>Figure 8</label><caption><title>Schematic representation of putative PXR roles in CSC survival and tumor recurrence</title><p>PXR expression in CSCs leads to enhanced transcription of PXR target genes promoting CSC plasticity by providing these cells with a defense arsenal that includes drug-metabolizing and transporter genes, enhanced capacity to deal with oxidative stress and genome alterations, and enhanced anti-apoptotic capabilities. Targeting PXR expression/activity using pharmacological inhibitors, may down regulate this multi-faceted protection against cytotoxic drugs and improve the efficiency of conventional chemotherapy in CRC patients through the sensitization of CSCs.</p></caption><graphic xlink:href="oncotarget-07-56558-g008"></graphic></fig><p>The large network of genes controlled by PXR in CSCs suggests that this receptor is a potential Achilles' heel for CSCs in colorectal cancers. Additionally, this may be true for other human cancers, as significant PXR expression levels have been detected in prostate, breast and ovarian cancers, where Aldefluor activity and ALDH1A1 expression are enriched in chemo-resistant CSCs [<xref rid="R42" ref-type="bibr">42</xref>–<xref rid="R44" ref-type="bibr">44</xref>]. Interestingly ALDH1A1 was among the most significantly deregulated genes after PXR knock-down or gain of function. Despite accumulating evidence in several cancers for the functional role of ALDH1A1 enzyme in CSC self-renewal and survival [<xref rid="R45" ref-type="bibr">45</xref>], the specific mechanisms involved in its regulation in CSCs remain unclear. Here we observed that PXR is an important driver of ALDH1A1 expression and activity in human colon CSC cells (Figures <xref ref-type="fig" rid="F5">5</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S4</xref> and <xref ref-type="supplementary-material" rid="SD1">S5</xref>). These results are in agreement with previous studies showing that Pxr activation increases both Aldh1a1 mRNA expression [<xref rid="R20" ref-type="bibr">20</xref>] and Pxr binding to the <italic>Aldh1a1</italic> gene [<xref rid="R46" ref-type="bibr">46</xref>] in mouse liver.</p><p>Finally, along with reports documenting the tumor-promoting [<xref rid="R47" ref-type="bibr">47</xref>] and chemoresistance properties [<xref rid="R48" ref-type="bibr">48</xref>] of PXR, and considering that Pxr knockout mice are viable, fertile and do not display major defects [<xref rid="R49" ref-type="bibr">49</xref>], our data point to PXR as a promising target to improve the efficiency of conventional chemotherapy. Interestingly, two molecules that were recently reported to interact synergistically with chemotherapies to eliminate CSCs, L-sulphoraphane and metformin [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R50" ref-type="bibr">50</xref>, <xref rid="R51" ref-type="bibr">51</xref>], are non-selective PXR inhibitors [<xref rid="R52" ref-type="bibr">52</xref>, <xref rid="R53" ref-type="bibr">53</xref>]. Thus, development of selective PXR-signaling inhibitors will represent an important step towards the validation of PXR as a clinically druggable target in comparison with these multi-targeted compounds.</p></sec><sec sec-type="supplementary-material" id="s4"><title>SUPPLEMENTARY MATERIALS FIGURES AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-07-56558-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e1396" position="anchor"></media></supplementary-material><supplementary-material content-type="local-data" id="SD2"><media mimetype="application" mime-subtype="xls" xlink:href="oncotarget-07-56558-s002.xls" orientation="portrait" xlink:type="simple" id="d35e1398" position="anchor"></media></supplementary-material><supplementary-material content-type="local-data" id="SD3"><media mimetype="application" mime-subtype="xls" xlink:href="oncotarget-07-56558-s003.xls" orientation="portrait" xlink:type="simple" id="d35e1400" position="anchor"></media></supplementary-material></sec></body><back><ack><p>We thank P. Crespy for his technical expertise and lab management, C. Duperray (IRBM, Montpellier) and M. Boyer (IGMM, Montpellier) from the Montpellier RIO Imaging platform for flow cytometry experiments, and M. Asari for her help in figure design. This work was supported by Grants from the Labex EpiGenMed and Université de Montpellier (F.R), Association pour la Recherche contre le Cancer (#16922 and SFI20121205749), Ligue régionale contre le cancer (Hérault, 6F11728PMBZ), the National Health and Medical Research Council of Australia (##1049561) and from Fundación Científica de la Asociación Española contra el Cáncer (GCB13131592CAST).</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>Authors have nothing to disclose.</p></fn><fn fn-type="con"><p><bold>Author contributions</bold></p><p>F.H, J.P and JM.P designed the research; C.P and F.H, J.P and JM.P designed part of the experiments, C.P, F.R, F.G, P.F, B.B, J.G, V.G, C.V, DV.B, L.C, J.K, A.P and JMP performed the experiments; C.P, F.B, M.G, C.G, F.H, J.P and JM.P analyzed the data; M.P, J.R, JF.B, M.G, A.C, JFB provided reagents/analytic tools; CP, FH, JP and JMP wrote the manuscript.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alwan</surname><given-names>A</given-names></name></person-group><article-title>World Health Organization</article-title><source>Disaster Med Public Health Prep</source><year>2007</year><volume>1</volume><fpage>7</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/DMP.0b013e3180676d3201273293-200707000-00008</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name></person-group><article-title>Treatment in advanced colorectal cancer: what when and how?</article-title><source>Br J Cancer</source><year>2009</year><volume>100</volume><fpage>1704</fpage><lpage>19</lpage><comment>6605061 [pii]</comment><pub-id pub-id-type="doi">10.1038/sj.bjc.6605061</pub-id><pub-id pub-id-type="pmid">19436303</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prud'homme</surname><given-names>GJ</given-names></name></person-group><article-title>Cancer stem cells and novel targets for antitumor strategies</article-title><source>Curr Pharm Des</source><year>2012</year><volume>18</volume><fpage>2838</fpage><lpage>49</lpage><pub-id pub-id-type="other">CPD-EPUB-20120228-014</pub-id><pub-id pub-id-type="pmid">22390767</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Dylla</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cho</surname><given-names>RW</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Gurney</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>EH</given-names></name><name><surname>Simeone</surname><given-names>DM</given-names></name><name><surname>Shelton</surname><given-names>AA</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name><name><surname>Castelli</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Phenotypic characterization of human colorectal cancer stem cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>10158</fpage><lpage>63</lpage><comment>0703478104 [pii]</comment><pmc-comment>10.1073/pnas.0703478104 </pmc-comment>
<pub-id pub-id-type="pmid">17548814</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci-Vitiani</surname><given-names>L</given-names></name><name><surname>Lombardi</surname><given-names>DG</given-names></name><name><surname>Pilozzi</surname><given-names>E</given-names></name><name><surname>Biffoni</surname><given-names>M</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Peschle</surname><given-names>C</given-names></name><name><surname>De Maria</surname><given-names>R</given-names></name></person-group><article-title>Identification and expansion of human colon-cancer-initiating cells</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>111</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/nature05384</pub-id><pub-id pub-id-type="pmid">17122771</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreso</surname><given-names>A</given-names></name><name><surname>O'Brien</surname><given-names>CA</given-names></name><name><surname>van Galen</surname><given-names>P</given-names></name><name><surname>Gan</surname><given-names>OI</given-names></name><name><surname>Notta</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name><name><surname>Ng</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Wienholds</surname><given-names>E</given-names></name><name><surname>Dunant</surname><given-names>C</given-names></name><name><surname>Pollett</surname><given-names>A</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>McPherson</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>543</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.1227670</pub-id><pub-id pub-id-type="pmid">23239622</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Alea</surname><given-names>MP</given-names></name><name><surname>Di Stefano</surname><given-names>AB</given-names></name><name><surname>Cammareri</surname><given-names>P</given-names></name><name><surname>Vermeulen</surname><given-names>L</given-names></name><name><surname>Iovino</surname><given-names>F</given-names></name><name><surname>Tripodo</surname><given-names>C</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Gulotta</surname><given-names>G</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name><name><surname>Stassi</surname><given-names>G</given-names></name></person-group><article-title>Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4</article-title><source>Cell Stem Cell</source><year>2007</year><volume>1</volume><fpage>389</fpage><lpage>402</lpage><comment>S1934-5909(07)00118-X [pii]</comment><pub-id pub-id-type="doi">10.1016/j.stem.2007.08.001</pub-id><pub-id pub-id-type="pmid">18371377</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dylla</surname><given-names>SJ</given-names></name><name><surname>Beviglia</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Chartier</surname><given-names>C</given-names></name><name><surname>Raval</surname><given-names>J</given-names></name><name><surname>Ngan</surname><given-names>L</given-names></name><name><surname>Pickell</surname><given-names>K</given-names></name><name><surname>Aguilar</surname><given-names>J</given-names></name><name><surname>Lazetic</surname><given-names>S</given-names></name><name><surname>Smith-Berdan</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Lewicki</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e2428</fpage><pub-id pub-id-type="pmid">18560594</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlos-Suarez</surname><given-names>A</given-names></name><name><surname>Barriga</surname><given-names>FM</given-names></name><name><surname>Jung</surname><given-names>P</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name><name><surname>Cespedes</surname><given-names>MV</given-names></name><name><surname>Rossell</surname><given-names>D</given-names></name><name><surname>Sevillano</surname><given-names>M</given-names></name><name><surname>Hernando-Momblona</surname><given-names>X</given-names></name><name><surname>da Silva-Diz</surname><given-names>V</given-names></name><name><surname>Munoz</surname><given-names>P</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Sancho</surname><given-names>E</given-names></name><name><surname>Mangues</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse</article-title><source>Cell Stem Cell</source><year>2011</year><volume>8</volume><fpage>511</fpage><lpage>24</lpage><comment>S1934-5909(11)00110-X [pii]</comment><pub-id pub-id-type="doi">10.1016/j.stem.2011.02.020</pub-id><pub-id pub-id-type="pmid">21419747</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollande</surname><given-names>F</given-names></name><name><surname>Pannequin</surname><given-names>J</given-names></name><name><surname>Joubert</surname><given-names>D</given-names></name></person-group><article-title>The long road to colorectal cancer therapy: searching for the right signals</article-title><source>Drug Resist Updat</source><year>2010</year><volume>13</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2009.01.002</pub-id><pub-id pub-id-type="pmid">20176501</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haraguchi</surname><given-names>N</given-names></name><name><surname>Utsunomiya</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Barnard</surname><given-names>GF</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><article-title>Characterization of a side population of cancer cells from human gastrointestinal system</article-title><source>Stem Cells</source><year>2006</year><volume>24</volume><fpage>506</fpage><lpage>13</lpage><comment>2005-0282 [pii]</comment><pub-id pub-id-type="doi">10.1634/stemcells.2005-0282</pub-id><pub-id pub-id-type="pmid">16239320</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>EH</given-names></name><name><surname>Hynes</surname><given-names>MJ</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Dontu</surname><given-names>G</given-names></name><name><surname>Appelman</surname><given-names>H</given-names></name><name><surname>Fields</surname><given-names>JZ</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Boman</surname><given-names>BM</given-names></name></person-group><article-title>Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>3382</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19336570</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olszewski</surname><given-names>U</given-names></name><name><surname>Liedauer</surname><given-names>R</given-names></name><name><surname>Ausch</surname><given-names>C</given-names></name><name><surname>Thalhammer</surname><given-names>T</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name></person-group><article-title>Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro</article-title><source>Cancers (Basel)</source><year>2011</year><volume>3</volume><fpage>1467</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.3390/cancers3011467</pub-id><pub-id pub-id-type="pmid">24212669</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achuthan</surname><given-names>S</given-names></name><name><surname>Santhoshkumar</surname><given-names>TR</given-names></name><name><surname>Prabhakar</surname><given-names>J</given-names></name><name><surname>Nair</surname><given-names>SA</given-names></name><name><surname>Pillai</surname><given-names>MR</given-names></name></person-group><article-title>Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>37813</fpage><lpage>29</lpage><comment>M110.200675 [pii]</comment><pub-id pub-id-type="doi">10.1074/jbc.M110.200675</pub-id><pub-id pub-id-type="pmid">21878644</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenoy</surname><given-names>A</given-names></name><name><surname>Butterworth</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>EH</given-names></name></person-group><article-title>ALDH as a marker for enriching tumorigenic human colonic stem cells</article-title><source>Methods Mol Biol</source><year>2012</year><volume>916</volume><fpage>373</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-980-8_27</pub-id><pub-id pub-id-type="pmid">22914954</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chikazawa</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tasaka</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Onishi</surname><given-names>H</given-names></name><name><surname>Katano</surname><given-names>M</given-names></name></person-group><article-title>Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells</article-title><source>Anticancer Res</source><year>2010</year><volume>30</volume><fpage>2041</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20651349</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sladek</surname><given-names>NE</given-names></name><name><surname>Kollander</surname><given-names>R</given-names></name><name><surname>Sreerama</surname><given-names>L</given-names></name><name><surname>Kiang</surname><given-names>DT</given-names></name></person-group><article-title>Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens</article-title><source>Cancer Chemother Pharmacol</source><year>2002</year><volume>49</volume><fpage>309</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s00280-001-0412-4</pub-id><pub-id pub-id-type="pmid">11914911</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>JM</given-names></name><name><surname>McKee</surname><given-names>DD</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Moore</surname><given-names>JT</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</article-title><source>J Clin Invest</source><year>1998</year><volume>102</volume><fpage>1016</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9727070</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynal</surname><given-names>C</given-names></name><name><surname>Pascussi</surname><given-names>JM</given-names></name><name><surname>Leguelinel</surname><given-names>G</given-names></name><name><surname>Breuker</surname><given-names>C</given-names></name><name><surname>Kantar</surname><given-names>J</given-names></name><name><surname>Lallemant</surname><given-names>B</given-names></name><name><surname>Poujol</surname><given-names>S</given-names></name><name><surname>Bonnans</surname><given-names>C</given-names></name><name><surname>Joubert</surname><given-names>D</given-names></name><name><surname>Hollande</surname><given-names>F</given-names></name><name><surname>Lumbroso</surname><given-names>S</given-names></name><name><surname>Brouillet</surname><given-names>JP</given-names></name><name><surname>Evrard</surname><given-names>A</given-names></name></person-group><article-title>Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation</article-title><source>Mol Cancer</source><year>2010</year><volume>9</volume><fpage>46</fpage><pub-id pub-id-type="pmid">20196838</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alnouti</surname><given-names>Y</given-names></name><name><surname>Klaassen</surname><given-names>CD</given-names></name></person-group><article-title>Tissue distribution ontogeny and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice</article-title><source>Toxicol Sci</source><year>2008</year><volume>101</volume><fpage>51</fpage><lpage>64</lpage><comment>kfm280 [pii]</comment><pub-id pub-id-type="doi">10.1093/toxsci/kfm280</pub-id><pub-id pub-id-type="pmid">17998271</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmen</surname><given-names>J</given-names></name><name><surname>Tozakidis</surname><given-names>IE</given-names></name><name><surname>Galla</surname><given-names>HJ</given-names></name></person-group><article-title>Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier</article-title><source>Brain Res</source><year>2013</year><volume>1491</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2012.10.060</pub-id><pub-id pub-id-type="pmid">23123212</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saigusa</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Toiyama</surname><given-names>Y</given-names></name><name><surname>Yokoe</surname><given-names>T</given-names></name><name><surname>Okugawa</surname><given-names>Y</given-names></name><name><surname>Ioue</surname><given-names>Y</given-names></name><name><surname>Miki</surname><given-names>C</given-names></name><name><surname>Kusunoki</surname><given-names>M</given-names></name></person-group><article-title>Correlation of CD133 OCT4 and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy</article-title><source>Ann Surg Oncol</source><year>2009</year><volume>16</volume><fpage>3488</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1245/s10434-009-0617-z</pub-id><pub-id pub-id-type="pmid">19657699</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Mo</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>EH</given-names></name></person-group><article-title>Celecoxib Downregulates CD133 Expression Through Inhibition of the Wnt Signaling Pathway in Colon Cancer Cells</article-title><source>Cancer Invest</source><year>2012</year><volume>31</volume><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.3109/07357907.2012.754458</pub-id><pub-id pub-id-type="pmid">23245395</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drocourt</surname><given-names>L</given-names></name><name><surname>Ourlin</surname><given-names>JC</given-names></name><name><surname>Pascussi</surname><given-names>JM</given-names></name><name><surname>Maurel</surname><given-names>P</given-names></name><name><surname>Vilarem</surname><given-names>MJ</given-names></name></person-group><article-title>Expression of CYP3A4 CYP2B6 and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>25125</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1074/jbc.M201323200</pub-id><pub-id pub-id-type="pmid">11991950</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmink</surname><given-names>BL</given-names></name><name><surname>Verheem</surname><given-names>A</given-names></name><name><surname>Van Houdt</surname><given-names>WJ</given-names></name><name><surname>Steller</surname><given-names>EJ</given-names></name><name><surname>Govaert</surname><given-names>KM</given-names></name><name><surname>Pham</surname><given-names>TV</given-names></name><name><surname>Piersma</surname><given-names>SR</given-names></name><name><surname>Borel Rinkes</surname><given-names>IH</given-names></name><name><surname>Jimenez</surname><given-names>CR</given-names></name><name><surname>Kranenburg</surname><given-names>O</given-names></name></person-group><article-title>The Secretome of Colon Cancer Stem Cells Contains Drug-metabolizing Enzymes</article-title><source>J Proteomics</source><year>2013</year><comment>S1874-3919(13)00373-4 [pii]</comment><pub-id pub-id-type="doi">10.1016/j.jprot.2013.06.027</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duong</surname><given-names>HQ</given-names></name><name><surname>Hwang</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Seong</surname><given-names>YS</given-names></name><name><surname>Bae</surname><given-names>I</given-names></name></person-group><article-title>Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells</article-title><source>Int J Oncol</source><year>2012</year><volume>41</volume><fpage>855</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.3892/ijo.2012.1516</pub-id><pub-id pub-id-type="pmid">22710732</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>A</given-names></name><name><surname>Teufel</surname><given-names>J</given-names></name><name><surname>Ringel</surname><given-names>F</given-names></name><name><surname>Bettstetter</surname><given-names>M</given-names></name><name><surname>Hoepner</surname><given-names>I</given-names></name><name><surname>Rasper</surname><given-names>M</given-names></name><name><surname>Gempt</surname><given-names>J</given-names></name><name><surname>Koeritzer</surname><given-names>J</given-names></name><name><surname>Schmidt-Graf</surname><given-names>F</given-names></name><name><surname>Meyer</surname><given-names>B</given-names></name><name><surname>Beier</surname><given-names>CP</given-names></name><name><surname>Schlegel</surname><given-names>J</given-names></name></person-group><article-title>Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma</article-title><source>Neuro Oncol</source><year>2013</year><volume>14</volume><fpage>1452</fpage><lpage>64</lpage><comment>nos270 [pii]</comment><pub-id pub-id-type="doi">10.1093/neuonc/nos270</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>MT</given-names></name><name><surname>Zou</surname><given-names>SW</given-names></name><name><surname>Cheng</surname><given-names>ZL</given-names></name><name><surname>Sun</surname><given-names>YP</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name><name><surname>Lei</surname><given-names>QY</given-names></name></person-group><article-title>NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><fpage>5453</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1172/JCI76611</pub-id><pub-id pub-id-type="pmid">25384215</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays</article-title><source>J Immunol Methods</source><year>2009</year><volume>347</volume><fpage>70</fpage><lpage>8</lpage><comment>S0022-1759(09)00195-1 [pii]</comment><pub-id pub-id-type="doi">10.1016/j.jim.2009.06.008</pub-id><pub-id pub-id-type="pmid">19567251</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Flier</surname><given-names>LG</given-names></name><name><surname>Haegebarth</surname><given-names>A</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>15</fpage><lpage>7</lpage><comment>S0016-5085(09)00800-2 [pii]</comment><pub-id pub-id-type="doi">10.1053/j.gastro.2009.05.035</pub-id><pub-id pub-id-type="pmid">19450592</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AE</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Poulin</surname><given-names>EJ</given-names></name><name><surname>Means</surname><given-names>AL</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><name><surname>Higginbotham</surname><given-names>JN</given-names></name><name><surname>Juchheim</surname><given-names>A</given-names></name><name><surname>Prasad</surname><given-names>N</given-names></name><name><surname>Levy</surname><given-names>SE</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><etal></etal></person-group><article-title>The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>146</fpage><lpage>58</lpage><comment>S0092-8674(12)00280-2 [pii]</comment><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.042</pub-id><pub-id pub-id-type="pmid">22464327</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maugeri-Sacca</surname><given-names>M</given-names></name><name><surname>Bartucci</surname><given-names>M</given-names></name><name><surname>De Maria</surname><given-names>R</given-names></name></person-group><article-title>DNA damage repair pathways in cancer stem cells</article-title><source>Mol Cancer Ther</source><year>2012</year><volume>11</volume><fpage>1627</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-1040</pub-id><pub-id pub-id-type="pmid">22844074</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>SC</given-names></name><name><surname>Park</surname><given-names>YY</given-names></name><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Lim</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Chu</surname><given-names>IS</given-names></name><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Beauchamp</surname><given-names>RD</given-names></name><name><surname>Yeatman</surname><given-names>TJ</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>1291</fpage><lpage>8</lpage><comment>gutjnl-2011-300812 [pii]</comment><pub-id pub-id-type="doi">10.1136/gutjnl-2011-300812</pub-id><pub-id pub-id-type="pmid">21997556</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Lian</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lan</surname><given-names>P</given-names></name></person-group><article-title>A subpopulation of CD24(+) cells in colon cancer cell lines possess stem cell characteristics</article-title><source>Neoplasma</source><year>2012</year><volume>59</volume><fpage>282</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4149/neo_2012_036</pub-id><pub-id pub-id-type="pmid">22329848</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>CXCR4-positive subset of glioma is enriched for cancer stem cells</article-title><source>Oncol Res</source><year>2011</year><volume>19</volume><fpage>555</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">22812188</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hlavata</surname><given-names>I</given-names></name><name><surname>Mohelnikova-Duchonova</surname><given-names>B</given-names></name><name><surname>Vaclavikova</surname><given-names>R</given-names></name><name><surname>Liska</surname><given-names>V</given-names></name><name><surname>Pitule</surname><given-names>P</given-names></name><name><surname>Novak</surname><given-names>P</given-names></name><name><surname>Bruha</surname><given-names>J</given-names></name><name><surname>Vycital</surname><given-names>O</given-names></name><name><surname>Holubec</surname><given-names>L</given-names></name><name><surname>Treska</surname><given-names>V</given-names></name><name><surname>Vodicka</surname><given-names>P</given-names></name><name><surname>Soucek</surname><given-names>P</given-names></name></person-group><article-title>The role of ABC transporters in progression and clinical outcome of colorectal cancer</article-title><source>Mutagenesis</source><year>2012</year><volume>27</volume><fpage>187</fpage><lpage>96</lpage><comment>ger075 [pii]</comment><pub-id pub-id-type="doi">10.1093/mutage/ger075</pub-id><pub-id pub-id-type="pmid">22294766</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giraldez</surname><given-names>MD</given-names></name><name><surname>Lozano</surname><given-names>JJ</given-names></name><name><surname>Cuatrecasas</surname><given-names>M</given-names></name><name><surname>Alonso-Espinaco</surname><given-names>V</given-names></name><name><surname>Maurel</surname><given-names>J</given-names></name><name><surname>Marmol</surname><given-names>M</given-names></name><name><surname>Horndler</surname><given-names>C</given-names></name><name><surname>Ortego</surname><given-names>J</given-names></name><name><surname>Alonso</surname><given-names>V</given-names></name><name><surname>Escudero</surname><given-names>P</given-names></name><name><surname>Ramirez</surname><given-names>G</given-names></name><name><surname>Petry</surname><given-names>C</given-names></name><name><surname>Lasalvia</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5′fluoruracil-based adjuvant chemotherapy</article-title><source>Int J Cancer</source><year>2012</year><volume>132</volume><fpage>1090</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/ijc.27747</pub-id><pub-id pub-id-type="pmid">22833293</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlert</surname><given-names>C</given-names></name><name><surname>Gaitzsch</surname><given-names>E</given-names></name><name><surname>Steinert</surname><given-names>G</given-names></name><name><surname>Mogler</surname><given-names>C</given-names></name><name><surname>Herpel</surname><given-names>E</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Jansen</surname><given-names>L</given-names></name><name><surname>Benner</surname><given-names>A</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Rahbari</surname><given-names>N</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Klupp</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy</article-title><source>Ann Surg Oncol</source><year>2012</year><volume>19</volume><fpage>4193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1245/s10434-012-2518-9</pub-id><pub-id pub-id-type="pmid">22878609</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>Y</given-names></name><name><surname>Matsunaga</surname><given-names>K</given-names></name><name><surname>Iijima</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>G</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>RM</given-names></name></person-group><article-title>The combination of 5-FU leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer</article-title><source>Anticancer Res</source><year>2010</year><volume>30</volume><fpage>403</fpage><lpage>8</lpage><comment>30/2/403</comment><pub-id pub-id-type="pmid">20332446</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>E</given-names></name><name><surname>Ji</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zha</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>LW</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>Expression of the PXR gene in various types of cancer and drug resistance</article-title><source>Oncol Lett</source><year>2013</year><volume>5</volume><fpage>1093</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1149</pub-id><pub-id pub-id-type="pmid">23599746</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Kanakasabai</surname><given-names>S</given-names></name><name><surname>Bright</surname><given-names>JJ</given-names></name></person-group><article-title>Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells</article-title><source>Br J Cancer</source><year>2011</year><volume>104</volume><fpage>448</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6606064</pub-id><pub-id pub-id-type="pmid">21224854</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>PE</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Ontiveros</surname><given-names>CS</given-names></name><name><surname>Salm</surname><given-names>SN</given-names></name><name><surname>Moscatelli</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>EL</given-names></name></person-group><article-title>High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells</article-title><source>Stem Cells</source><year>2009</year><volume>27</volume><fpage>2220</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/stem.135</pub-id><pub-id pub-id-type="pmid">19544409</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Hur</surname><given-names>MH</given-names></name><name><surname>Charafe-Jauffret</surname><given-names>E</given-names></name><name><surname>Monville</surname><given-names>F</given-names></name><name><surname>Dutcher</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Kleer</surname><given-names>CG</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Schott</surname><given-names>A</given-names></name><name><surname>Hayes</surname><given-names>D</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome</article-title><source>Cell Stem Cell</source><year>2007</year><volume>1</volume><fpage>555</fpage><lpage>67</lpage><comment>S1934-5909(07)00133-6 [pii]</comment><pub-id pub-id-type="doi">10.1016/j.stem.2007.08.014</pub-id><pub-id pub-id-type="pmid">18371393</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landen</surname><given-names>CN</given-names><suffix>Jr</suffix></name><name><surname>Goodman</surname><given-names>B</given-names></name><name><surname>Katre</surname><given-names>AA</given-names></name><name><surname>Steg</surname><given-names>AD</given-names></name><name><surname>Nick</surname><given-names>AM</given-names></name><name><surname>Stone</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>LD</given-names></name><name><surname>Mejia</surname><given-names>PV</given-names></name><name><surname>Jennings</surname><given-names>NB</given-names></name><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Bast</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Coleman</surname><given-names>RL</given-names></name><name><surname>Lopez-Berestein</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer</article-title><source>Mol Cancer Ther</source><year>2010</year><volume>9</volume><fpage>3186</fpage><lpage>99</lpage><comment>1535-7163.MCT-10-0563 [pii]</comment><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0563</pub-id><pub-id pub-id-type="pmid">20889728</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomita</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>A</given-names></name></person-group><article-title>Aldehyde dehydrogenase 1A1 in stem cells and cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>11018</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6920</pub-id><pub-id pub-id-type="pmid">26783961</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>JY</given-names></name><name><surname>Gunewardena</surname><given-names>SS</given-names></name><name><surname>Rockwell</surname><given-names>CE</given-names></name><name><surname>Klaassen</surname><given-names>CD</given-names></name></person-group><article-title>ChIPing the cistrome of PXR in mouse liver</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><fpage>7943</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq654</pub-id><pub-id pub-id-type="pmid">20693526</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Venkatesh</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Goetz</surname><given-names>R</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Kaubisch</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Pullman</surname><given-names>J</given-names></name><name><surname>Whitney</surname><given-names>K</given-names></name><name><surname>Kuro</surname><given-names>OM</given-names></name><name><surname>Roig</surname><given-names>AI</given-names></name><etal></etal></person-group><article-title>Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice</article-title><source>J Clin Invest</source><year>2011</year></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pondugula</surname><given-names>SR</given-names></name><name><surname>Mani</surname><given-names>S</given-names></name></person-group><article-title>Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response</article-title><source>Cancer Lett</source><year>2013</year><volume>328</volume><fpage>1</fpage><lpage>9</lpage><comment>S0304-3835(12)00518-6 [pii]</comment><pub-id pub-id-type="doi">10.1016/j.canlet.2012.08.030</pub-id><pub-id pub-id-type="pmid">22939994</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staudinger</surname><given-names>JL</given-names></name><name><surname>Goodwin</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Hawkins-Brown</surname><given-names>D</given-names></name><name><surname>MacKenzie</surname><given-names>KI</given-names></name><name><surname>LaTour</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Klaassen</surname><given-names>CD</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Reinhard</surname><given-names>J</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>3369</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1073/pnas.05155169898/6/3369</pub-id><pub-id pub-id-type="pmid">11248085</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>HA</given-names></name><name><surname>Iliopoulos</surname><given-names>D</given-names></name><name><surname>Tsichlis</surname><given-names>PN</given-names></name><name><surname>Struhl</surname><given-names>K</given-names></name></person-group><article-title>Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>7507</fpage><lpage>11</lpage><comment>0008-5472.CAN-09-2994 [pii]</comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2994</pub-id><pub-id pub-id-type="pmid">19752085</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rausch</surname><given-names>V</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Kallifatidis</surname><given-names>G</given-names></name><name><surname>Baumann</surname><given-names>B</given-names></name><name><surname>Mattern</surname><given-names>J</given-names></name><name><surname>Gladkich</surname><given-names>J</given-names></name><name><surname>Wirth</surname><given-names>T</given-names></name><name><surname>Schemmer</surname><given-names>P</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name><name><surname>Zoller</surname><given-names>M</given-names></name><name><surname>Salnikov</surname><given-names>AV</given-names></name><name><surname>Herr</surname><given-names>I</given-names></name></person-group><article-title>Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>5004</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">20530687</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krausova</surname><given-names>L</given-names></name><name><surname>Stejskalova</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Vrzal</surname><given-names>R</given-names></name><name><surname>Dvorak</surname><given-names>Z</given-names></name><name><surname>Mani</surname><given-names>S</given-names></name><name><surname>Pavek</surname><given-names>P</given-names></name></person-group><article-title>Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene</article-title><source>Biochem Pharmacol</source><year>2011</year><volume>82</volume><fpage>1771</fpage><lpage>80</lpage><comment>S0006-2952(11)00674-5 [pii]</comment><pub-id pub-id-type="doi">10.1016/j.bcp.2011.08.023</pub-id><pub-id pub-id-type="pmid">21920351</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Poulton</surname><given-names>EJ</given-names></name><name><surname>Grun</surname><given-names>F</given-names></name><name><surname>Bammler</surname><given-names>TK</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name><name><surname>Thummel</surname><given-names>KE</given-names></name><name><surname>Eaton</surname><given-names>DL</given-names></name></person-group><article-title>The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor</article-title><source>Mol Pharmacol</source><year>2007</year><volume>71</volume><fpage>220</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17028159</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartley</surname><given-names>AN</given-names></name><name><surname>Parikh</surname><given-names>N</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Roe</surname><given-names>DJ</given-names></name><name><surname>Buckmeier</surname><given-names>JA</given-names></name><name><surname>Corley</surname><given-names>L</given-names></name><name><surname>Phipps</surname><given-names>RA</given-names></name><name><surname>Gallick</surname><given-names>G</given-names></name><name><surname>Lance</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>PA</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name></person-group><article-title>Colorectal adenoma stem-like cell populations: associations with adenoma characteristics and metachronous colorectal neoplasia</article-title><source>Cancer Prev Res (Phila)</source><year>2013</year><volume>6</volume><fpage>1162</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-13-0113</pub-id><pub-id pub-id-type="pmid">24008128</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpentino</surname><given-names>JE</given-names></name><name><surname>Hynes</surname><given-names>MJ</given-names></name><name><surname>Appelman</surname><given-names>HD</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Steindler</surname><given-names>DA</given-names></name><name><surname>Scott</surname><given-names>EW</given-names></name><name><surname>Huang</surname><given-names>EH</given-names></name></person-group><article-title>Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>8208</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1132</pub-id><pub-id pub-id-type="pmid">19808966</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MP</given-names></name><name><surname>Fleming</surname><given-names>JB</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Choi</surname><given-names>W</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>McConkey</surname><given-names>DJ</given-names></name><name><surname>Evans</surname><given-names>DB</given-names></name><name><surname>Gallick</surname><given-names>GE</given-names></name></person-group><article-title>ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e20636</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0020636</pub-id><pub-id pub-id-type="pmid">21695188</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002832 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002832 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:5302934
|texte= Pregnane X-receptor promotes stem cell-mediated colon cancer relapse
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:27448961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |